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PREFACE
Note to the reader:
Chapter 1 defines the clinical problem and provides a brief introduction to
conventional methods of handling geometric uncertainties inherent in the delivery of
radiation for the treatment of cancer. Chapter 1 also presents the rationale of anatomical
motion model development for improved radiation therapy outcomes.
Chapters 2-4 of this dissertation include patient-specific motion models based on
standard and regularized Principal Component Analysis (PCA) approaches, and
dosimetric outcomes that follow radiation treatments based on these models.
Finally, Chapter 5 presents conclusions and discussion of future directions.

iv

TABLE OF CONTENTS
Dedication

_________________________________________________________ ii

Acknowledgments _____________________________________________________ iii
Preface

_________________________________________________________ iv

List of Tables ________________________________________________________ viii
List of Figures _________________________________________________________ ix
List of Abbreviations ___________________________________________________ xii
Chapter 1 “Introduction” _________________________________________________ 1
Geometric Uncertainties in Radiation Therapy __________________________ 1
Conventional Method of Handling Geometric Uncertainties ________________ 3
Conventional Method of Handling OAR Uncertainties _______________ 4
Conventional Method of Handling Delineation Uncertainties __________ 6
Role of Image-Guided Radiation Therapy and Adaptive Radiation Therapy
in Handling Uncertainties _____________________________________ 6
Motivation for Motion Model Development in Radiation Therapy for Head and Neck
Patients ________________________________________________________ 7
Statement of the Problem __________________________________________ 7
Chapter 2 “Standard Principal Component Analysis Model of Anatomical Changes in
Head and Neck Patients” ________________________________________________ 9
Introduction _____________________________________________________ 9
Materials and Methods ____________________________________________ 9
Clinical and Simulated Image Data ______________________________ 9
Deformation Vector Fields Data _______________________________ 12
Clinical Deformation Vector Fields _____________________________ 13
Synthetic Deformation Vector Fields ____________________________ 13

v

PCA Models – Standard PCA _________________________________ 16
Predictive Model ___________________________________________ 17
Model Evaluation __________________________________________ 19
Results _______________________________________________________ 22
Qualitative Evaluation _______________________________________ 22
Quantitative Evaluation ______________________________________ 24
Discussion _____________________________________________________ 26
Qualitative Evaluation _______________________________________ 26
Quantitative Evaluation ______________________________________ 28
Conclusion _____________________________________________________ 30
Chapter 3 “Regularized Principal Component Analysis Model of Anatomical Changes in
Head and Neck Patients” _______________________________________________ 31
Introduction ____________________________________________________ 31
Materials and Methods ___________________________________________ 31
PCA Models – Regularized PCA ______________________________ 31
Results _______________________________________________________ 32
Qualitative Evaluation _______________________________________ 32
Quantitative Evaluation ______________________________________ 35
Discussion _____________________________________________________ 44
Qualitative Evaluation _______________________________________ 44
Quantitative Evaluation ______________________________________ 45
PCA Performance __________________________________________ 46
Prior Applications of PCA ____________________________________ 50
Potential for Regularized PCA ________________________________ 51
vi

Study Limitations __________________________________________ 53
Conclusion _____________________________________________________ 55
Chapter 4 “Dosimetric Assessment of Effects of Systematic and Random Fraction-toFraction Anatomical Changes in Head and Neck Patients” _____________________ 56
Introduction ____________________________________________________ 56
Materials and Methods ___________________________________________ 57
Results _______________________________________________________ 61
Discussion _____________________________________________________ 70
Conclusion _____________________________________________________ 74
Chapter 5 “Conclusions and Future Work” __________________________________ 75
Summary of Findings_____________________________________________ 75
Future Work ____________________________________________________ 76
Appendix “Standard Principal Component Analysis Matrix Operations” ____________ 79
References

________________________________________________________ 82

Abstract

________________________________________________________ 91

Autobiographical Statement _____________________________________________ 94

vii

LIST OF TABLES
Table 2.1 SPCA: R2 correlation coefficient of performed linear regression of weights ,
versus fraction number f, averaged for all 10 patients (Step M2, Materials and
Methods) ....................................................................................................................... 22
Table 2.2 SPCA: Results of gamma analysis of eCT versus pCT: percent gamma values
exceeding one, using 3%/3mm criteria.......................................................................... 26
Table 3.1 RPCA: R2 correlation coefficient of performed linear regression of weights ,
versus fraction number f, averaged for all 10 patients (Chapter 2, Step M2, Materials and
Methods) ....................................................................................................................... 33
Table 3.2 RPCA: Results of gamma analysis of eCT versus pCT: percent gamma values
exceeding one, using 3%/3mm criteria. Gamma analysis results for the SPCA models are
shown in the parentheses ............................................................................................. 37
Table 4.1 Planned, simulated, modeled and accumulated dosimetric parameters for the
patients (in Gy). The relative percentage difference from the planned dose presented in
parentheses .................................................................................................................. 69

viii

LIST OF FIGURES
Figure 2.1: Blended pCT and wCT images of four (out of ten) patients; A - parotid gland
shrinkage, B - parotid gland shrinkage and weight loss, C - Tumor shrinkage in the
oropharynx, D - lymph node shrinkage in the left .......................................................... 10
Figure 2.2: In-house developed interactive software tool (Matlab®) to perform warping of
the images..................................................................................................................... 11
Figure 2.3: Early, linear and late models of patient response........................................ 15
Figure 2.4: Relationship between measured and predicted DVFs ................................ 19
Figure 2.5: SPCA: Results of SPCA models generated from synthetic DVFs for patient D,
for whom PCA modeling gave the best results. ............................................................. 23
Figure 2.6: SPCA: Results of SPCA models generated from synthetic DVFs for patient A,
for whom PCA modeling gave the worst results ............................................................ 24
Figure 2.7: SPCA: Mean lengths of the image error as a function of the number of fractions
F. Vector lengths are scaled by 1/√ . Both the mean and standard deviation of the
lengths of the image error vectors decrease as F increases ......................................... 25
Figure 3.1: RPCA: Results of RPCA models generated from synthetic DVFs for patient
D, for whom PCA modeling gave the best results ......................................................... 34
Figure 3.2: RPCA: Results of RPCA models generated from synthetic DVFs for patient A,
for whom PCA modeling gave the worst results ............................................................ 35
Figure 3.3: RPCA: Mean lengths of the image error as a function of the number of
fractions F. Vector lengths are scaled by 1/√ . Both the mean and standard deviation of
the lengths of the image error vectors decrease as F increases. SPCA results are
represented by dashed grey lines ................................................................................. 36
Figure 3.4: Leading EDVF weight averaged for SPCA and RPCA models generated from
synthetic DVFs for a patient who experienced parotid shrinkage. Results are shown for
the PCA models generated from first 5 fractions (top), half of the fractions (middle) and
all-but-last fraction (bottom)........................................................................................... 38
Figure 3.5: RPCA: 1st and 2nd EDVF weights for RPCA models generated from synthetic
DVFs for a patient who experienced parotid shrinkage. A linear response model was
assumed (Chapter 2, Materials and Methods), and κ = 5 in equation 2.1, ensuring that
DVFs incorporated approximately 5 times the level of random motion seen in clinical
CBCTs........................................................................................................................... 39
Figure 3.6: RPCA: 1st, 2nd and 3rd EDVF weights for RPCA models generated from clinical
DVFs for a patient who experienced weight loss in the left neck................................... 41
ix

Figure 3.7: RPCA: Predicted DVFs and corresponding eigenimages (heat map
representation of DVF vector magnitudes) for the same patient as in Figure 3.7. DVF
arrow directions represent pull-back displacement fields from the planning anatomy (pCT)
to the final treatment fraction. The magnitude of displacements is at the same scale as
the background image ................................................................................................... 42
Figure 3.8: RPCA: RPCA: Predicted DVFs and corresponding eigenimages (heat map
representation of DVF vector magnitudes) for the patient with parotid shrinkage and
weight loss as a major anatomical change during radiation therapy ............................. 43
Figure 4.1 DVHs for the left parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only
component superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses B) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions......................................................................................................... 62
Figure 4.2: DVHs for the left parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line ...................................................................................................................... 63
Figure 4.3: DVHs for the right parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only
component superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses B) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown) ........................................................................................... 64
Figure 4.4: DVHs for the right parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line ...................................................................................................................... 64
Figure 4.5: DVHs for the spinal cords of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only
component superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses B) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown) ........................................................................................... 65

x

Figure 4.6: DVHs for the spinal cords of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line ...................................................................................................................... 66
Figure 4.7: Patient 2: (A) pCT (red) overlaid on the resampled CBCT of the last treatment
fraction. CBCT is resampled using the diffeomorphic demons DVF compressed with the
factor 7; (B) pCT (red) overlaid on the eCT (green). Red arrows show the underestimation
of the parotids movement due to the large CF used for the DVFs; (C) pCT (red) overlaid
on the last fraction CBCT (green) .................................................................................. 67
Figure 4.8: Patients 1 and 2: Comparison of the planned DVHs (blue) for the left parotid
glands vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH .................... 67
Figure 4.9: Patient 1 and 2: Comparison of the planned DVHs (blue) for the right parotid
glands vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH .................... 68
Figure 4.10: Patient 1 and 2: Comparison of the planned DVHs (blue) for the spinal cords
vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH ............................... 68

xi

LIST OF ABBREVIATIONS
3D........................................................................................................ Three Dimensional
AAA ................................................................................. Analytical Anisotropic Algorithm
ART ....................................................................................... Adaptive Radiation Therapy
CBCT ....................................................................................................... Cone-Beam CT
CF ..................................................................................................... Compression Factor
CT ................................................................................................ Computed Tomography
CTV ............................................................................................... Clinical Target Volume
DIR ................................................................................... Deformable Image Registration
DVF ............................................................................................ Deformation Vector Field
DVH.............................................................................................Dose Volume Histogram
epCT ............................................................................................................Estimated CT
EDVF................................................................................................................ Eigen-DVF
GNU ......................................................................................................... GNU’s Not Unix
GSL ................................................................................................ GNU Scientific Library
GTV ................................................................................................. Gross Tumor Volume
GU ............................................................................................... Geometric Uncertainties
H&N........................................................................................................... Head and Neck
HU ........................................................................................................... Hounsfield Units
ICRU ........................................................... International Commission on Radiation Units
IGRT............................................................................. Image-Guided Radiation Therapy
IMRT .................................................................... Intensity Modulated Radiation Therapy
IRB ........................................................................................... Institutional Review Board

xii

Linac..................................................................................................... Linear Accelerator
NTCP .................................................................. Normal Tissue Complication Probability
OAR ............................................................................................................ Organ-at-Risk
OSG .......................................................................................... Organ Sample Generator
PC .................................................................................................... Principal Component
PCA .................................................................................... Principal Component Analysis
pCT ................................................................................................................Planning CT
PRV ................................................................................................ Planning Risk Volume
PTV ............................................................................................. Planning Target Volume
RAM .......................................................................................... Random-Access Memory
QA ........................................................................................................ Quality Assurance
QUANTEC.............................Quantitative Analysis of Normal Tissue Effects in the Clinic
RPCA ............................................................. Regularized Principal Component Analysis
SPCA ................................................................. Standard Principal Component Analysis
TPS ....................................................................................... Treatment Planning System
wCT ................................................................................................................. Warped CT

xiii

1
CHAPTER 1 “INTRODUCTION”

Geometric Uncertainties in Radiation Therapy
Achieving tumor control with intensity modulated radiation therapy (IMRT) is both
a geometric and a biological problem. The geometric aspect of the problem is to deliver
a sufficient radiation dose to the tumor to sterilize it, while constraining dose to
surrounding normal tissues to acceptable levels. The biological aspect of the problem is
to understand issues such as dose-response relationships for tumors and normal tissues,
the effect of different treatment regimens (e.g., hypofractionation), and the possible
benefits of adjuvant chemotherapeutic agents. The biological aspect is not considered in
this work.
In this work novel approaches to the geometric aspects of photon IMRT delivery
to head and neck (H&N) were investigated – motion models of anatomical changes for
H&N patients, to forecast anatomy and dose on future fractions, were constructed and
tested.
The geometric problem may be summarized as follows. A physician delineates the
gross tumor volume (GTV) and expands it by an appropriate margin to encompass
expected microscopic disease. The resulting structure, the clinical target volume (CTV),
is defined in the patient anatomical coordinate system (i.e., the coordinate system of the
planning computed tomography (CT) image). If, in every treatment fraction, the patient
could be aligned to the linear accelerator (linac) with perfect accuracy, allowing the linac
isocenter to be located exactly at its intended position in the tumor, treatment could be
planned and delivered to the CTV.
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In reality, even when image guidance is used to carefully align the patient to the
linac, the patient’s intended position can still be offset from the isocenter1. Causes of
offsets include: (i) setup errors2 (imprecisions and inaccuracies inherent in the alignment
tools used to position the patient with respect to the linac at the start of each fraction),
and (ii) target (CTV) motion during delivery of each fraction3, 4. The above effects are
random — target shape and position assume different random values, characterized by
probability distributions, for each treatment course and fraction. Both effects create
uncertainty in the position of the isocenter, and are accordingly referred to as geometric
uncertainties (GUs).
Organ-at-risk (OAR) motion is a third category of GU5. At the start of a treatment
fraction, an OAR can be offset from the isocenter by a different amount than in the
planning CT (pCT), and can move relative to the isocenter (and CTV) during the fraction.
The planning implications of OAR setup uncertainty and motion are different than for
targets. One can reasonably hope to reduce target uncertainties through accurate (e.g.,
image-guided) setup. However, OAR motion is independent of the target, and cannot be
eliminated through target alignment.
Delineation uncertainty is a fourth category of GU6-8. Delineation of gross tumor
and organs-at-risk (OARs) on the planning CT is typically a manual operation subject to
physician judgment. Errors or uncertainties can occur as a result of poor quality images,
contouring shortcuts (such as contour interpolation across CT slices), time pressure on
physicians, or unconscious bias when e.g., the physician is overly conservative when
contouring targets in the vicinity of an OARs. Like setup uncertainties and tissue motion,
delineation errors create a degree of geometric uncertainty in the true position of targets
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and OARs with respect to the linac, and can therefore be addressed using the same
planning techniques. Automated segmentation methods based on structure atlases9
have the potential to reduce delineation uncertainties, but residual errors persist even
with these methods.
Changes in patient anatomy during the course of radiation therapy (e.g. weight
loss, tumor shrinkage, lymph node shrinkage, etc.) represent a fifth category of GU. One
of the major reasons for such anatomical changes is the tissues’ response to the radiation,
causing e.g., tumor shrinkage, localized edema, etc. However, anatomical changes can
occur for other reasons, e.g. general weight loss due to change in eating habits.
Numerous research papers discuss importance of anatomical changes during radiation
therapy10-14.
The above five GUs should be considered during the treatment planning process
in order to accurately perform radiation therapy.

Conventional Method of Handling Geometric Uncertainties
The conventional method of accounting for uncertainties in the position of the CTV
relative to the linac (i.e., isocenter) is to expand the CTV to a planning target volume
(PTV), and plan treatment to the PTV. Beams are configured, and IMRT inverse planning
is performed, to ensure that in the static plan (i.e., the conventional plan generated prior
to the start of treatment using the pCT image) the entire PTV receives the prescription
dose (or a dose that is acceptably close to the prescription dose). In this case the PTV
represents a bounding envelope within which one expects to find the entire CTV for every
treatment fraction. This framework is described in ICRU reports 50 and 6215, 16.
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The size of the CTV-to-PTV margin controls the tradeoff between target and
normal tissue doses. The margin needs to be large enough to ensure the CTV is covered
most of the time, but not significantly larger, since that can result in OARs receiving
unnecessary dose, leading to toxicity. The requirement that the CTV be covered (e.g.,
enclosed by the prescription dose isodose surface) “most of the time” is a coverage
criterion. In the widely-used margin formula proposed by van Herk et al17, “most of the
time” is made mathematically precise by interpreting it to mean “95% minimum dose to
CTV in 90% of patients”. However, alternative approaches to PTV margins are possible.
In clinical practice, margins are often set to round values such as 0.5 cm or 1.0 cm based
on clinical conventions. In that case, the margin is justified by pointing to prior clinical
experience that demonstrates generally acceptable treatment outcomes. There is a large
number of published studies investigating appropriate CTV-to-PTV margin size for
different treatment sites18-21.

Conventional Method of Handling OAR Uncertainties
In considering geometric uncertainties, much of the published literature focuses on
target coverage and CTV-to-PTV margins. The ICRU framework15,

16

also allows for

planning organ at risk volumes (PRVs) to be defined around OAR. The concept is similar
to that of a PTV. The OAR-to-PRV margin is intended to create a ‘buffer zone’ around the
OAR that can absorb geometric uncertainties. If OAR optimization criteria are applied to
the PRV instead of the OAR, those constraints should be respected in the presence of
geometric uncertainties.
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However, practical application of PRVs is not straightforward. In the case of
targets, there is generally a single prescription dose to be applied uniformly across the
PTV. In that case, simple treatment models of the type used by van Herk et al.22 can be
used to estimate the amount by which the prescription dose isodose surface “pulls back”
towards the CTV, as a result of the cumulative blurring of beams over multiple fractions.
One can then compensate for this pull-back via the CTV-to-PTV margin.
For OARs there are typically multiple optimization criteria at different tolerance
doses. The effect of blurring on the corresponding isodose surfaces will vary according
to dose. For high doses, the isodose surface will pull back into the high dose region. For
lower doses, it may push out from the high dose region, closer to the OARs. Based on
the van Herk model, there is consequently no single OAR-to-PRV margin that will match
all dose-volume criteria. Stroom and Heijmen23 have investigated PRVs, concluding that
they change the underlying OAR volume “in such a manner that dose-volume constraints
stop making sense”. For these reasons, PRVs are not widely used in clinical practice.
The non-use of PRVs means that the effects of geometric uncertainties (e.g., organ
motion) on OAR are largely ignored. Failure to explicitly account for geometric
uncertainties is thought to be one barrier to acquiring reliable and clinically useful
biological outcomes models for OAR. The QUANTEC report24 summarizes clinical data
and models for a number of OAR. QUANTEC chapter 2025 discusses the need to record
“true dose” (i.e., dose delivered in the presence of geometric uncertainties) as opposed
to planned dose, stating that “only careful studies that include estimates of (true dose) will
allow us to confidently disentangle the effects of dosimetry and radiobiological sensitivity”.
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Conventional Method of Handling Delineation Uncertainties
In conventional clinical planning, delineation uncertainties are mostly ignored. One
interpretation of current practice would be that delineation uncertainties are assumed to
be sufficiently small that they are safely absorbed within current GTV-to-CTV and CTVto-PTV margins, i.e., there is no need to explicitly account for them. However, the
evidence from inter- and intra-observer studies26-28 is that delineation uncertainties can
be large relative to typical margins. Furthermore, as time goes on, advances in treatment
delivery and imaging are reducing setup errors, and enabling organ motion to be
quantitatively modeled more accurately than was previously possible. For these reasons,
one can reasonably argue that delineation uncertainties need to be accurately quantified,
and explicitly accounted for in treatment planning7.

Role of Image-Guided Radiation Therapy and Adaptive Radiation Therapy in
Handling Uncertainties
Image-guided radiation therapy (IGRT)29 largely focuses on more accurate tumor
targeting and tracking, and is less concerned with OAR motion. Recognizing that IGRT
cannot mitigate the effects of changes in tumor shape, or motion of OAR with respect to
the tumor, adaptive radiation therapy (ART)30, 31 provides a complementary strategy in
which the treatment plan is periodically updated throughout the treatment course. Both
IGRT and ART have the goal of reducing geometric uncertainties. ART is likely to be most
effective in cases where inter-fraction anatomic changes are significant with respect to
intra-fraction changes. ART can be performed offline or online, with online planning being
more effective, but more challenging due to the requirement to re-plan and perform quality
assurance within a narrow time window.
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Motivation for Motion Model Development in Radiation Therapy for Head and Neck
Patients
IMRT in H&N cancer conforms very precisely to the three-dimensional (3D) shape
of the tumor by modulating the intensity of the radiation beam in multiple small volumes.
IMRT also allows higher radiation doses to be focused to regions within the tumor while
minimizing the dose to surrounding normal critical structures32-35. Thus, the therapeutic
index can potentially be increased by using IMRT as opposed to classical 3D conformal
radiation therapy (RT).
However, conformal dose distributions are sensitive to GUs presented in patients,
like daily setup errors or changes in the anatomy during treatment course due to the
reasons mentioned above. For positional errors, online correction strategies like IGRT
can help to minimize the effects of systematic and random setup errors36-38. However,
residual setup uncertainties still exist and IGRT alone cannot compensate for non-rigid
deformations of the anatomy39.
ART is a potential solution for this problem. Although the concept of ART was
proposed more than a decade ago31, clinical implementation has lagged in part because
of the inability to answer practical questions such as: What anatomical changes are
important? How do we measure them? When to trigger re-planning? And how best to
perform the re-planning?

Statement of the Problem
Having models of anatomical changes over the course of treatment is essential to
answer the above questions. Models should take into account not only rigid body
transformations but also deformations, and be capable of extracting useful information
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about changes in patient anatomy, ideally early in the radiation therapy course.
Several mathematical models have been proposed to account for patient motion4046.

Among them, principal component analysis (PCA) was chosen in this study to model

anatomical changes47. PCA is potentially a powerful and efficient method and is capable
of identifying eigenmodes which are most responsible for the observed variations48. PCA
compresses large multidimensional and unorganized data to a low-dimensional system
of basis vectors (eigenvectors), representing major modes of anatomical change.
PCA models have been used for dosimetric evaluation of virtual prostate treatment
courses47, geometric coverage estimation49, lung deformation modeling50, automatic
organ segmentation51 and organ shape variability analysis52. However, to date, the
implementation of PCA models has not been utilized for extracting systematic changes in
patient anatomy during the H&N radiation therapy course. More information and material
about PCA will be introduced in Chapter 2.
This work presents initial results on PCA modeling for characterizing systematic
anatomical changes in H&N patients using daily cone-beam CT (CBCT) images. The goal
is to reliably identify systematic anatomical changes early in the treatment course, in order
to trigger re-planning decisions. A further goal is to capture normal tissue and tumor
changes for treatment response assessment.
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CHAPTER 2 “STANDARD PRINCIPAL COMPONENT ANALYSIS MODEL OF
ANATOMICAL CHANGES IN HEAD AND NECK PATIENTS”

Introduction
The central idea of principal component analysis (PCA) is to reduce the
dimensionality of a data set consisting of a large number of interrelated variables, while
retaining as much as possible of the variation present in the data set48. To achieve this
PCA performs orthonormal transformation of an original data set to a new set of variables
called principal components (PC), which are orthonormal, and therefore uncorrelated to
each other. The first PC is defined in such a way that it accounts for the largest possible
variability in the data, while each succeeding PC in turn has the largest possible variability
under the constraint that it is orthogonal to all preceding PCs.
PCA was first introduced in 1901 by K. Pearson53. Since then it became a handy
tool which is used widely in predictive modeling.
This chapter discusses the develop of standard PCA (SPCA) models of anatomical
change from daily CBCTs of H&N patients, and assesses the possibility of using these in
adaptive radiation therapy and to extract quantitative information for treatment response
assessment.

Materials and Methods
Clinical and Simulated Image Data
Ten H&N patients with daily CBCT imaging were retrospectively selected under an
Institutional Review Board (IRB) approved protocol. Each patient experienced different
systematic changes during the course of radiotherapy, like parotid shrinkage, weight loss,
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tumor shrinkage in the oropharynx area, lymph node shrinkage in the left neck area, and
base of tongue shrinkage. In Figure 2.1 patients which experienced such systematic
changes are presented: parotid shrinkage (patient A), parotid shrinkage plus weight loss
(patient B), tumor shrinkage in the oropharynx area (patient C) and lymph node shrinkage
in the left neck area (patient D). Arrows indicate the region of change.

Figure 2.1 Blended pCT and wCT images of four (out of ten) patients; A parotid gland shrinkage, B - parotid gland shrinkage and weight loss, C Tumor shrinkage in the oropharynx, D - lymph node shrinkage in the left
neck.
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For each patient, a synthetic warped CT (wCT) was generated from the pCT image
using an in-house developed interactive software tool. The interface of this tool is shown
in Figure 2.2.

Figure 2.2 In-house developed interactive software tool (Matlab®) to perform warping of the
images
The goal of the warping was to simulate the predominant localized systematic
anatomical change over the duration of the patient treatment (Figure 2.1, arrows). So, for
patient A, for example, the sole difference between the pCT and wCT was the deformation
of the parotids and immediately adjacent tissue. Away from the parotids, the pCT and
wCT matched exactly. The interactive warping tool was developed in Matlab®
(MathWorks Inc., Natick, MA). It incorporated the barrel distortion function54 and pencil
tool, and allowed the user to iteratively expand, contract and shape a region of the pCT
anatomy using a computer mouse. The generated wCTs were inspected by a radiation
oncologist with expertise in H&N to ensure clinical realism.
The generated wCTs constitute digital phantoms, allowing PCA results to be
evaluated in a controlled setting where the exact nature of anatomical change is known
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a priori. Results below compare PCA’s ability to extract anatomical change from digital
phantoms (specifically, synthetic CBCTs generated from the wCT), as well as from real
patients (i.e., clinical CBCTs). For clinical images, anatomical change is not known a priori
and likely contains a variety of random components due to fraction-to-fraction setup
uncertainties, posture variations, etc. Clinical images and deformation vector fields
(DVFs) are therefore expected to be a greater challenge for the PCA technique.

Deformation Vector Fields Data
Prior to DVF generation, clinical or synthetic CBCT images were rigidly aligned
with pCTs using bony skull and C2-C3 cervical vertebrae, to ensure all DVFs were relative
to the fixed skull. The pCTs acted as reference imaged. DVFs were generated and
manipulated in the Pinnacle® Treatment Planning System (TPS), utilizing Pinnacle
plugins in conjunction with the open source GNU Scientific Library (GSL)55 for matrix
operations. DVFs for all patients were generated using Pinnacle’s diffeomorphic demons
algorithm56-58. A compression factor (CF) of 7 was used, meaning that a single DVF voxel
covers 7 CT voxels (~ 7 mm) in the coronal and sagittal (X and Y) directions. This was
done in order to keep PCA model generation numerically feasible. DVF voxel size in the
axial (Z) direction was 3mm independent of the CF.
DVFs were restricted to a bounding box of the approximate size of the patient head
and neck in order to speed up calculation. Bounding boxes were set sufficiently large to
accommodate all anatomies. DVF values were set to zero for voxels outside the (pCT)
patient body to avoid spurious deformations that are an artifact of the deformable image
registration (DIR) algorithm. Given the number of voxels M, a DVF in 3D space is

13
represented as a vector of length 3M, representing X, Y and Z displacements.
It is worth noting the mathematical conventions that apply to DVFs. Each DVF is
defined between a fixed image and a moving image. In the present case, the fixed image
is the pCT, and the moving image is the wCT or CBCT. The DVF is defined on (i.e., is the
same size as) the voxel grid in the fixed image. However, as explained by Yang59, the
DVF is a pull-back motion field. Each element of the DVF is a 3D vector (arrow) from a
point in the fixed image to the matching point in the moving image. Consequently, one
‘applies’ the DVF to the moving image (wCT or CBCT) to recover the fixed image (pCT).
In visual terms, given the moving image, one “pulls back” tissue volumes at arrow tips to
the corresponding arrow bases, to recover the fixed image.

Clinical Deformation Vector Fields
In the following description a patient’s ith CBCT is denoted CBCTi. Clinical DVFs
were generated as follows:
,

=

→

DC,i denotes the clinical DVF from pCT to CBCTi. It models systematic plus random
change from planning to fraction i. The differential DVF, which models the motion
difference between two successive fractions, is defined as follows:
,

=

,

−

,

In the case of clinical images, the final available CBCT for the patient was regarded
as the end-of-treatment anatomy (similar to the wCT).

Synthetic Deformation Vector Fields
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Synthetic DVFs were generated using the following process:
=

→

DW denotes the DVF from pCT to synthetic wCT. It models systematic change from
planning to end of treatment, based on the artificial deformation in the wCT. For a
simulated treatment course of 35 fractions, let

,

denote the systematic DVF (i.e., the

DVF including only systematic change) from planning to the ith fraction, i = 1,...,35.
Systematic DVFs were calculated using 3 different time models of patient response,
linear, early and late:
,

=

!

"

,

=

1−

,

=

!#

linear
!#

$35 − &'( "

$& − 1'( "

early
late

In the above equations, the quantity in square brackets is the fraction of overall
systematic change relative to the start of treatment. It ranges from zero in fraction 1 to
one in fraction 35. This quantity is plotted in Figure 2.3. In the early (late) model,
approximately 75% (25%) of change has occurred by the middle of treatment. These
models are used to test PCA’s ability to extract systematic motion from DVFs early in the
treatment. For example, if PCA is asked to estimate systematic change from the first 5
treatment fractions, the late model presents PCA with much smaller systematic change
(i.e., less information) from which to generate its model. The visual results of this test,
averaged for SPCA and regularized PCA will be presented in the Results section of
Chapter 3 to avoid repetitiveness in the Chapters, since this test showed almost identical
behavior for both approaches.
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Figure 2.3 Early, linear and late models of patient response
Random changes were added to the synthetic DVFs as follows. Random DVFs DR
were modeled as scaled linear combinations of the DDC,i :

)

= * ∑ ,

,

, where

, - .0,10 are uniformly distributed random weights summing to one, which vary from
fraction to fraction, and * is a scaling parameter taking the values 1, 3 or 5, that is fixed
for each treatment course. The case * = 1 approximates the magnitude of random
motion present in clinical CBCTs. Cases * = 3 12 5 artificially increase the magnitude of
random motion, to test PCA’s ability to extract systematic changes in the presence of
increased random motion.
Finally, the synthetic DVF DSR,i for fraction i, incorporating both systematic and
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random changes, was defined as follows:
=

),

,

+

)

=

,

+ * ∑ ,

,

(2.1)

Note that DR varies from fraction to fraction and between simulated treatment
courses, as determined by the random number generator. In equation 2.1, the + symbol
indicates element-by-element addition of DVFs.

PCA Models – Standard PCA
This section describes the generation of a patient-specific SPCA model. Let D =
[D1, ..., DF] be an 3M x F matrix, whose column Df is a DVF of length 3M, where M is the
total number of voxels. In a clinical scenario, Df is the DVF from the planning CT to the
fraction f CBCT, f = 1, 2, ..., f ≤ N, where N is the number of fractions in the treatment
course. Input data for PCA modeling is typically made zero-mean by first subtracting the
mean DVF. Without loss of generality, we assume that the mean DVF 4 has already been
subtracted from each of the Df . DVFs from the first F fractions are used to build a model
that can be used to predict anatomical changes for the remaining fractions. Let E = [E1,
..., EF] be an 3M x F matrix, whose columns Ef are eigenvectors, here referred as
eigenDVFs (EDVFs). PCA solves the following constrained optimization problem for E:
min‖ : − ;;< : ‖
8

subject to ;< ; = =>

(2.2)

where IF is the F x F identity matrix and, for arbitrary matrix ? = @A B, ‖∙‖ is the Frobenius
norm: ‖?‖ = DE2F G∑ , A ( H. The solution of equation 2.2 is a set of orthonormal EDVFs
Ef, each of which is derived from an eigenvector of the covariance matrix I = :< :/M. The
solution E can be obtained by using standard matrix operations to find the eigenvalues
and eigenvectors of C. Further details about matrix operations used in this work to build
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SPCA model are given in the Appendix. The resulting SPCA model is fully specified by
the pair ( 4 ,E). An arbitrary DVF D (3M x 1 column vector) may be expressed in matrix
form
= 4 + ; + -

(2.3)

where w is a (F x 1) column vector of EDVF weights wj, and - is an 3M x 1 column vector
of errors -K . The error vector - represents any variation present in D that is not
expressible using a linear combination of the F EDVFs.
In the case of simulated treatment courses, SPCA models were generated from
the first F = 5, 18 or 34 synthetic DVFs DSR,i . These scenarios simulate the situation
where a PCA model is generated after the first week of treatment (F=5), the first half of
the 35-fraction course (F=18), and the complete course, except for the final fraction
(F=34). In the case of clinical images, SPCA models were generated from the available
15 – 35 DC,i , utilizing the initial 5, approximately half, and all but the final DC,i.

Predictive Model
The magnitude of a PCA eigenvalue reflects the degree of variation in the DVF
dataset that is contributed along the direction of the corresponding EDVF. EDVFs with
the largest eigenvalues should account for the major modes of anatomical change. If PCA
is successful, the expectation is that systematic components will be captured in the
leading EDVFs. Random components will be captured in trailing EDVFs, or in the error
vector - in equation 2.3.
Once a PCA model has been generated using the first F DVFs, producing F
EDVFs, one has the option of using a subset of K leading EDVFs (K ≤ F) to predict the
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major mode of anatomical change for subsequent fractions. If, for example, there is only
one major mode of anatomical change (e.g., tumor shrinkage), and that mode is captured
in the first EDVF, then a satisfactory predictive model may be achieved using K = 1.
Additionally, the PCA modeling process makes no assumptions regarding how
major modes of motion evolve during treatment. PCA EDVFs capture the direction but
not the time-varying magnitude of anatomical changes. After generation of the PCA
model, observed DVFs can be expressed as a linear combination of EDVFs (equation
(2.3), where the weights w will in general vary as treatment progresses. The trajectory of
weights w will indicate whether treatment response is early, linear or late, as in Fig. 2.3.
The default predictive model given below makes the assumption that evolution is linear.
However, this approach can be generalized to model early or late response, provided one
has sufficient knowledge to justify those models.
The following step-wise procedure was adopted to build a linear predictive model:
M1.
weights

Using equation 2.3, estimate the weight vector
,

) corresponding to each of the input DVFs Df from which the PCA model was
= G

generated:

(F x 1 column vector of

<
− 4 H ;. Weight

,

for f = 1, ..., F represents the evolving

contribution of EDVF L to anatomical change over fractions 1, ..., F.
M2.
weights

Separately for each value of j = 1, ..., F, perform a linear regression of
,

versus fraction number f. (For DVFs generated from clinical CBCTs, omit

points for fractions where the CBCT is missing.) The intercept and slope of the linear fit
to

,

are denoted by M and N respectively.
M3.

Estimate the DVF at fraction f, F < f ≤ N, by
O = 4 + ;P $M + N ∙ Q'

(2.4)
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where M and N are the K x 1 column vectors of M and N , and EK is the 3M x K
matrix, whose columns Ej are the first K EDVFs.
The relationship between measured DVFs (i.e., input DVFs Df in step M1) and
predicted DVFs (output DVFs from equation 2.4) is illustrated in Figure 2.4. The
orientation of DVF arrows is from fixed image to moving image, enabling CBCTs to be
mapped to the pCT. In principle, these DVFs can be inverted to give DVFs that will map
the pCT to predicted CBCTs for fractions F+1, ..., N. PCA-predicted DVFs are evaluated
using criteria outlined in the next section.

pCT

wCT
PCA predicted
Measured
DVFs

DVFs & CBCTs
...

CBCTF+1
CBCT1

...

CBCTN

CBCTF
CBCTF+1

PCA model from first F
clinical DVFs

CBCTN

clinical CBCTs

Figure 2.4 Relationship between measured and predicted DVFs

Model Evaluation
A hypothesis of this study is that the PCA model can successfully separate
systematic from random anatomical changes, capturing systematic changes in a few
leading EDVFs. One indicator of success is that, in step M2 above, the weights

,

associated with leading EDVFs exhibit non-zero slopes N , high R2 values and, more
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generally, smooth and consistent evolution with fraction number f. Conversely, weights
,

associated with trailing EDVFs should exhibit near-zero slopes, low R2, and purely

random variation with fraction number f. A further qualitative indicator of PCA success is
that the areas where leading EDVFs are non-zero are restricted to localized parts of the
anatomy where systematic changes are occurring.
PCA models may also be evaluated quantitatively. This can be done by using the
PCA model to warp the end-of-treatment anatomy to the predicted anatomy at the time
of simulation. In this way one obtains an estimated planning CT, or epCT. Then one can
compare epCT with the true planning CT (pCT) to assess how well the PCA model
reproduces anatomical changes during treatment. The specific steps for generating epCT
are:
S1.

For simulated treatments, apply O

S2.

For clinical CBCT images, let fE denote the fractions of the final CBCT

R

from equation 2.4 to the wCT to get

epCT.

image. Apply O

S

from equation (4) to CBCT S to get epCT.

Agreement between the pCT and epCT quantifies the difference between the real
and estimated planning anatomies ‖pCT − epCT‖. Note that the PCA model is intended
to capture only systematic anatomical changes. The end-of-treatment anatomy, from
which epCT is generated, will also incorporate random changes. Consequently, the
difference metric

‖pCT − epCT‖ will reflect how well PCA does at extracting the

systematic component of anatomical change, but it will also reflect the effect of random
anatomical changes not included in the model, and DIR uncertainties inherent in the DVFs
used to construct the PCA model. Finally, in the case of the clinical CBCT images, epCT
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is obtained by applying a modeled DVF to the end-of-treatment CBCT. Consequently, in
this case epCT will include an increased level of noise inherent in CBCT (versus CT)
images. This also will tend to increase the value of ‖pCT − epCT‖.
We define images error vector L Y as the difference between pCT and epCT
images:
L Y = Z[\ − ]Z[\ Y

(2.5)

where epCTF is the estimated CT obtained from the PCA model that is generated from
the first F fractions DVFs. L Y is a vector of length M. Each element of L Y is the error in
the estimated CT number for the corresponding voxel.
For PCA models based on clinical CBCTs, where one is limited to the available
CBCTs, we define the patient-specific distance metric to be the root mean square CT
number difference:
Y (
‖Z[\ − ][\ Y ‖ = ^ ∑_
`a $L '
_

(2.6)

For PCA models based on synthetic CBCT images generated from wCT, it is
possible to perform S simulations, where each simulation generates a different realization
of random changes throughout the treatment course. In this case we define the patientspecific distance metric to be the root mean square CT number difference, averaged over
simulations:
‖Z[\ − ][\ Y ‖ =

∑ba ^

_

Y (
∑_
`a $L '

(2.7)

In addition to these distance metrics, 3D gamma indices60 were calculated
between pCT and epCT images using 3% / 3mm criteria (3% difference in Hounsfield
Units (HU), and 3mm distance-to-agreement). ‖pCT − epCT‖ and gamma values were
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calculated for PCA models generated using the first five fractions, half of the treatment
fractions, and all but last treatment fraction.
Results
Qualitative Evaluation
Table 2.1 shows that for both simulated (linear, * = 1) and clinical cases, the
correlation coefficient R2 of EDVF weights are significant only for the first EDVF — in
Table 2.1, cases where R2 > 0.6 are shaded.

EDVF1

EDVF2

EDVF3

EDVF4

EDVF5

Simulated SPCA (linear)
cases

Clinical cases

Fx_5

0.38 ± 0.34

0.24 ± 0.07

Fx_half

0.82 ± 0.39

0.62 ± 0.19

Fx_all_but_last

0.89 ± 0.14

0.65 ± 0.21

Fx_5

0.51 ± 0.32

0.01 ± 0.01

Fx_half

0.03 ± 0.05

0.03 ± 0.04

Fx_all_but_last

0.11 ± 0.20

0.01 ± 0.02

Fx_5

0.36 ± 0.34

0.21 ± 0.05

Fx_half

0.14 ± 0.21

0.06 ± 0.08

Fx_all_but_last

0.01 ± 0.02

0.04 ± 0.05

Fx_5

0.43 ± 0.30

0.10 ± 0.03

Fx_half

0.05 ± 0.07

0.13 ± 0.08

Fx_all_but_last

0.01±0.02

0.14 ± 0.19

Fx_5

0.38 ± 0.29

0.05 ± 0.07

Fx_half

0.09 ± 0.10

0.07 ± 0.08

Fx_all_but_last

0.01 ± 0.01

0.05 ± 0.01

Table 2.1 SPCA: R2 correlation coefficient of performed linear regression of weights cd,e
versus fraction number f, averaged for all 10 patients (Step M2, Materials and Methods).
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For EDVFs 2-5, R2 coefficients are generally much lower. For simulated cases, R2
values for EDVFs 2-5 in the 5-fraction PCA models (Fx_5) are higher (0.36 – 0.51). But
those R2 values drop substantially when more DVFs (fractions) are included in the PCA
models, indicating that EDVFs 2-5 are not reliably capturing systematic changes. Based
on Table 2.1, PCA models in this work utilize only one, or at most several, leading EDVFs.
For synthetic CBCTs, the estimated anatomy epCT at the time of simulation was
reconstructed by applying O

R

(equation 2.4) to the wCT image. Figure 2.5 shows results

for patient D, for whom PCA gave the best results (out of the 10 patients studied). Figure
2.6 shows results for patient A, for whom PCA gave the worst results. In each case, top
panels show pCT (red) overlaid on the epCT (green). The left-most panel (A) is for a PCA

Figure 2.5 SPCA: Results of SPCA models generated from synthetic DVFs for patient D, for
whom PCA modeling gave the best results
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Figure 2.6 SPCA: Results of SPCA models generated from synthetic DVFs for patient A, for
whom PCA modeling gave the worst results
model constructed from the first 5 treatment fractions. The middle panel (B) is for a PCA
model constructed from the first 18 treatment fractions. The right-most panel (C) is for a
PCA model constructed from all but the last treatment fraction. Lower panels in Figures
2.5 and 2.6 show the projections of all 35 simulated DVFs onto the leading EDVF. The
error bars represent ± one standard deviation of EDVF weight values across simulated
treatment courses having different random motion components. To generate these
results, 10 different treatment courses were simulated for each patient.

Quantitative Evaluation
Figure 2.7 plots mean lengths of the image error vectors,‖pCT − epCT‖, equations
(2.6) and (2.7), as a function of the number of fractions F from which the PCA model is
generated: Patient A, PCA model generated from clinical CBCTs and DVFs; patient D,
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PCA model generated from clinical CBCTs and DVFs; patient A, PCA model generated
from synthetic wCT and DVFs; patient D, PCA model generated from synthetic wCT and
DVFs.
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Figure 2.7 SPCA: Mean lengths of the image error as a function of the number of fractions
F. Vector lengths are scaled by f/√g. Both the mean and standard deviation of the lengths
of the image error vectors decrease as F increases
Although plotted against F = 5, 18, 34, clinical PCA models utilized the first 5
CBCTs, approximately half of available CBCTs, and all but the final CBCT. Vector lengths
are scaled by 1/√

and plotted points are shifted slightly horizontally to avoid overlap of

the error bars.
Table 2.2 shows results of gamma analysis of epCT versus pCT. Specifically, it
shows the percentage of gamma values exceeding one, using 3%/3mm criteria for the
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simulated and clinical cases of patients D (best case out of 10 patients) and patient A
(worst case out of 10) for the SPCA models generated from first 5 fractions, half of the
treatment fractions and all-but-last fraction.

Simulated

Clinical

Patient D (best case
out of 10 patients)

Patient A (worst case
out of 10 patients)

5 FX

0.25

0.50

HALF

0.14

0.24

ALL_BUT_LAST

0.11

0.18

5 FX

2.39

4.15

HALF

1.33

2.07

ALL_BUT_LAST

1.15

2.02

Table 2.2 SPCA: Results of gamma analysis of epCT versus pCT: percent gamma values
exceeding one, using 3%/3mm criteria
Discussion
Qualitative Evaluation
Table 2.1 shows that R2 coefficients for the simulated linear cases for the first
EDVF have values ~1, while for EDVFs 2-5 values are much less. This result shows that
the leading first EDVF can capture the simulated linear major mode of anatomical change,
while succeeding EDVFs capture residual errors and noise. The R2 coefficient is a good
metric to check if EDVFs captured the major anatomical change only if you expect these
changes to be linear. This is not always the case during radiation therapy in real patients
– changes could be non-linear and could appear early or late in the treatment.
But as stated in the Materials and Methods section above, the PCA modeling
process makes no assumptions regarding how major modes of motion evolve during
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treatment – it’s just metric we use to evaluate it (like R2 for the linear changes). PCA
EDVFs capture the direction but not the magnitude of anatomical changes. Therefore,
using proper metrics (i.e. splines or polynomials) it is possible to check if EDVFs captured
major anatomical changes for non-linear cases. The results and discussion supporting
this statement are presented in Chapter 3.
Figure 2.5 shows that, given the right conditions, SPCA modeling is capable of
extracting the major mode of anatomical change during head and neck radiation therapy.
The leading EDVF coefficients show a smooth progression during treatment, and the
more CBCTs that are included in the SPCA model, the better the model becomes. This
is indicated by a progressive tightening of the standard deviations of EDVF weights as
one moves from model A (5 fractions), to model B (18 fractions), to model C (34 fractions).
In Figure 2.5 the modeled anatomical change, left neck lymph node shrinkage, is
large — it affects a relatively large volume of the patient’s anatomy. SPCA searches for
EDVFs that can explain variability across CBCT images. If the modeled anatomical
change is large, the SPCA technique is more easily able to ‘extract’ the major deformation
mode(s) from noisy data. This explains why patient D has the best PCA model across the
ten sampled patients.
In Figure 2.6 (patient A), the modeled anatomical change, bilateral parotid
shrinkage, is relatively small — it affects a localized volume around the parotids. In this
case SPCA finds it more difficult to isolate the anatomical change from other random
variations that are present in the CBCT images. For this reason, the SPCA model is not
as good as for patient D. The PCA models for F=5 and F=18 fractions show a fairly weak
linear progression of the leading EDVF coefficient, and the standard deviation of the
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coefficients is large, indicating that the SPCA technique is having a difficult time ‘locking
onto’ the major deformation mode. Only when the treatment course is almost complete
(column C, F=34) does the SPCA model become good enough to predict the anatomy,
with a higher level of confidence.
One of the conclusions of this study is that SPCA — i.e., PCA applied directly to
DVFs without any further enhancement or refinement — will find it difficult to extract
smaller systematic anatomical changes from daily CBCT images. Where changes are
small, SPCA will tend to be confused by other random motion present in the images, and
the resulting PCA models will have diminished ability to predict or extrapolate anatomical
changes.

Quantitative Evaluation
Figure 2.7 shows that larger HU errors occur for the SPCA models generated from
clinical CBCTs (lines (a) and (b)), than those generated from synthetic images and DVFs
(lines (c) and (d)). Synthetic DVFs were generated artificially by inserting one known
anatomical change into the planning CT. Regions of the patient anatomy that were not
affected by the change were identical throughout the treatment course, except for added
random changes. This represents a best-case scenario for SPCA modeling. Having only
one systematic change present in the images makes it easier for the SPCA method to
capture that change within the leading EDVF.
Clinical CBCTs may include several types of systematic anatomical change — for
example, lymph node shrinkage in conjunction with weight loss. Clinical CBCTs can also
include random motion of the anatomy outside of the region directly involved in the
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systematic change. Finally, evolution of the systematic change in clinical CBCTs may not
follow a simple linear progression, as was the case with the synthetic DVFs. For these
reasons, SPCA finds it more difficult to extract useful models from clinical CBCT images.
This conclusion is reinforced by the gamma results in Table 2.2. Those results
show that the number of voxels in epCT that disagree with pCT by more than 3% or 3
mm is fairly modest for the SPCA models generated from synthetic DVFs, but much larger
in models generated from clinical CBCTs.
Quantitative results shown in Figure 2.7 and Table 2.2 may be used as an indirect
way of testing the accuracy of DVFs, or the accuracy of the reconstructed epCT (acquired
by applying the last-fraction DVF from equation 2.4 to the pCT image) versus the pCT
image. Although thorough testing of DVFs accuracy was out of the scope of this work,
results of the quantitative analysis give an idea of how the number of fractions used to
build a model and random changes presented in simulated and clinical data affect the
quality of the last-fraction DVF and overall accuracy of the epCT with respect to the pCT
image.
Within this work we evaluated whether SPCA models generated from clinical
CBCTs could potentially be improved by including more than one leading EDVF. That is,
using K ≥ 2 as explained in the Predictive Model section above. However, for clinical
SPCA models the R2 coefficient was moderately good for the leading EDVF, but quite
poor for EDVFs 2-5 (see Table 2.1), indicating that there was no improvement derived
by including any EDVFs beyond the first. The conclusion of this work is that, particularly
for smaller anatomical changes, SPCA becomes ‘confused’ by the variety of deformations
and noise in clinical CBCT images, and therefore fails to extract major modes of
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systematic change that are known to be present. In order to successfully model
anatomical change in clinical CBCT images, the basic SPCA technique will need to be
refined.
In Chapter 3 more extensive discussion about SPCA model and its comparison to
more advanced regularized PCA (RPCA) model will be presented.

Conclusion
For the H&N patients treated with external beam radiation therapy, a SPCA model
is a potential tool to identify patient anatomy changes early in the treatment course, and
to make educated adaptive re-planning decisions. This study used synthetic (but realistic)
DVFs, as well as clinical CBCTs, to evaluate the ability of the SPCA method to extract
useful models of anatomical change. In particular, a primary goal of this work was to
evaluate the ability of SPCA to separate systematic from random changes present in
CBCT images.
The study shows that under the right conditions, SPCA can capture the major
mode of systematic anatomical deformation in the leading EDVF. However, SPCA is most
successful at identifying large changes (e.g., significant lymph node shrinkage), and less
successful at identifying small changes (e.g., smaller changes in parotid glands).
Additionally, SPCA is challenged by the variety of deformations and noise in clinical CBCT
images, and therefore fails to extract major modes of systematic change that are known
to be present. In order to successfully model anatomical change in clinical CBCT images,
the basic SPCA technique will be refined using the regularized approach described in
Chapter 3.
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CHAPTER 3 “REGULARIZED PRINCIPAL COMPONENT ANALYSIS MODEL OF
ANATOMICAL CHANGES IN HEAD AND NECK PATIENTS”

Introduction
The purpose of this Chapter is to reveal, building on the Materials and Methods
section presented in Chapter 2, the details of developing regularized PCA (RPCA) models
of anatomical changes from daily CBCTs images of H&N patients, and assess their
potential use in ART, and for extracting quantitative information for treatment response
assessment.
The general motivation to build the RPCA model is the same as for the SPCA (i.e.,
modeling of anatomical change, see the Introduction section in Chapter 2). The specific
motivation is to improve on the SPCA results given in Chapter 2.

Materials and Methods
The dataset, DVFs and predictive model used to build the RPCA model are the
same as described in Chapter 2. The difference is in the constraint optimization problem
(equation 2, Chapter 2) one needs to solve to get EDVFs.

PCA Models – Regularized PCA
For reasons discussed below, standard PCA (SPCA) can produce EDVFs that are
noisy and not physically meaningful. RPCA offers a solution for this problem. The method
of generation of a patient-specific regularized RPCA model is similar to the SPCA model
described earlier. The difference lies in the constrained optimization problem for E that
PCA needs to solve for the regularized PCA approach:
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min{ ‖: − ;;< : ‖( + i ∑Ỳa j$]` ' + i( ∑Ỳa ∑
8

_
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]` $D ' }

(3.1)

subject to ;< ; = =>
where IF is the F x F identity matrix, D = $A , l , m '′, i ≥ 0 is a smoothness parameter
and the corresponding term j$]` ' is a roughness penalty designed to enhance
smoothness of EDVFs ]` , i( ≥ 0 is a sparseness parameter and the corresponding term
is the L1 Lasso penalty designed to promote sparse patterns in EDVFs by shrinking some
principal component loadings to zero. The explanation of the methods used to solve the
constrained optimization problem for sparse data sets could be found in Wang and
Huang61.
RPCA models are dependent on the choices of smoothing parameter i and
sparseness parameter i( . Both parameters were empirically chosen with the assumption
in mind that DVFs are intrinsically smooth, so the smoothness parameter was chosen to
be less significant than the sparseness parameter. After experimentation, the following
rules were adopted to set i and i( : i =

_∗Y
qqq

and i( =

_∗Y
qq

.

As before, the resulting PCA model is fully specified by the pair ( 4 , E), and an
arbitrary DVF may be again expressed using equation 2.3. As for SPCA, RPCA models
were generated from the first F = 5, 18 or 34 synthetic DVFs DSR,i . In the case of clinical
images, RPCA models were generated from the available 15 – 35 DC,i , utilizing the initial
5, approximately half, and all but the final DC,i.

Results
Qualitative Evaluation
Table 3.1 shows that for both simulated (linear, * = 1) and clinical cases, the
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correlation coefficient R2 of EDVF weights are significant only for the first EDVF — in
Table 3.1, cases where R2 > 0.6 are shaded.
For EDVFs 2-5, R2 coefficients are generally much lower. For simulated cases, R2
values for EDVFs 2-5 in the 5-fraction RPCA models (Fx_5) are higher (0.16 – 0.39). But
those R2 values drop substantially when more DVFs (fractions) are included in the RPCA
models, indicating that EDVFs 2-5 are not reliably capturing systematic changes.

EDVF1

EDVF2

EDVF3

EDVF4

EDVF5

Simulated RPCA
(linear) cases

Clinical cases

Fx_5

0.57 ± 0.24

0.54 ± 0.21

Fx_half

0.87 ± 0.19

0.77 ± 0.22

Fx_all_but_last

0.94 ± 0.19

0.81 ± 0.18

Fx_5

0.39 ± 0.13

0.27 ± 0.10

Fx_half

0.14 ± 0.05

0.11 ± 0.05

Fx_all_but_last

0.21 ± 0.11

0.29 ± 0.05

Fx_5

0.16 ± 0.27

0.10 ± 0.05

Fx_half

0.15 ± 0.22

0.15 ± 0.17

Fx_all_but_last

0.07 ± 0.19

0.12 ± 0.12

Fx_5

0.27 ± 0.20

0.14 ± 0.09

Fx_half

0.32 ± 0.11

0.20 ± 0.18

Fx_all_but_last

0.10±0.12

0.12 ± 0.06

Fx_5

0.30 ± 0.17

0.04 ± 0.09

Fx_half

0.12 ± 0.11

0.09 ± 0.11

Fx_all_but_last

0.04 ± 0.07

0.09 ± 0.15

Table 3.1 RPCA: R2 correlation coefficient of performed linear regression of weights cd,e
versus fraction number f, averaged for all 10 patients (Chapter 2, Step M2, Materials and
Methods).
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The estimated anatomy epCT at the time of simulation was reconstructed by
applying O

R

(equation 2.4) to the wCT image. Figures 3.1 and 3.2 show result for the

same patients as for SPCA model. Figure 3.1 shows results for the patient D, for whom
RPCA gave the best results (out of the 10 patients studied). Figure 3.2 shows results for
patient A, for whom RPCA gave the worst results. In each case, top panels show pCT
(red) overlaid on the epCT (green). The left-most panel (A) is for a RPCA model
constructed from the first 5 treatment fractions. The middle panel (B) is for a RPCA model
constructed from the first 18 treatment fractions. The right-most panel (C) is for a RPCA
model constructed from all but the last treatment fraction. Lower panels in Figures 3.1
and 3.2 show the projections of all 35 simulated DVFs onto the leading EDVF. The error
bars represent ± one standard deviation of EDVF weight values across simulated
treatment courses having different random motion components. To generate these
results, 10 different treatment courses were simulated for each patient.

Figure 3.1 RPCA: Results of RPCA models generated from synthetic DVFs for patient D, for
whom PCA modeling gave the best results
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Figure 3.2 RPCA: Results of RPCA models generated from synthetic DVFs for patient A, for
whom PCA modeling gave the worst results
Quantitative Evaluation
Figure 3.3 plots mean lengths of the image error vectors,‖pCT − epCT‖, equations
(2.6) and (2.7), as a function of the number of fractions F from which the RPCA model is
generated: Patient A, RPCA model generated from clinical CBCTs and DVFs; patient D,
RPCA model generated from clinical CBCTs and DVFs; patient A, RPCA model
generated from synthetic wCT and DVFs; patient D, RPCA model generated from
synthetic wCT and DVFs.
Although plotted against F = 5, 18, 34, clinical RPCA models utilized the first 5
CBCTs, approximately half of available CBCTs, and all but the final CBCT. Vector lengths
are scaled by 1/√

and plotted points are shifted slightly horizontally to avoid overlap of
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the error bars. SPCA model results (similar to the Figure 2.7) also plotted on Figure 3.3
as a grey dashed lines for comparison.
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Figure 3.3 RPCA: Mean lengths of the image error as a function of the number of fractions
F. Vector lengths are scaled by f/√g. Both the mean and standard deviation of the lengths
of the image error vectors decrease as F increases. SPCA results are represented by dashed
grey lines.

Table 3.2 shows results of gamma analysis of epCT versus pCT. Specifically, it
shows the percentage of gamma values exceeding one, using 3%/3mm criteria for the
simulated and clinical cases of patients D (best case out of 10 patients) and patient A
(worst case out of 10) for the RPCA models generated from first 5 fractions, half of the
treatment fractions and all-but-last fraction. Gamma analysis results for the SPCA models
are shown in the parentheses.
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Simulated

Clinical

Patient D (best case
out of 10 patients)

Patient A (worst case
out of 10 patients)

5 FX

0.15 (0.25)

0.42 (0.50)

HALF

0.08 (0.14)

0.17 (0.24)

ALL_BUT_LAST

0.06 (0.11)

0.10 (0.18)

5 FX

2.13 (2.39)

3.83 (4.15)

HALF

1.13 (1.33)

1.91 (2.07)

ALL_BUT_LAST

0.97 (1.15)

1.64 (2.02)

Table 3.2 RPCA: Results of gamma analysis of epCT versus pCT: percent gamma values
exceeding one, using 3%/3mm criteria. Gamma analysis results for the SPCA models are
shown in the parentheses.
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Figure 3.4 shows averaged
results

for

RPCA

models

generated from synthetic DVFs for
a patient with parotid shrinkage. In
these models, * (equation (2.1)) is
equal to one. Each panel shows
the projection of synthetic DVFs
onto the leading EDVF (i.e., weight
,

from step M1 Chapter 2,

Materials and Methods). The top
panel shows results for PCA
models built from the first 5 of 35
CBCTs; middle panel, 18 CBCTs;
bottom panel, 34 CBCTs.
Each panel in Figure 3.4
shows weights for the linear, early
and late response models (section
2.4). To generate each curve,
RPCA models were created for 5
Figure 3.4 Leading EDVF weight averaged for
SPCA and RPCA models generated from
synthetic DVFs for a patient who experienced
parotid shrinkage. Results are shown for the PCA
models generated from first 5 fractions (top), half
of the fractions (middle) and all-but-last fraction
(bottom)

simulated

treatment

courses.

Plotted data points are mean
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weights. The error bars represent ± one standard deviation around the mean.

Figure 3.5 RPCA: 1st and 2nd EDVF weights for RPCA models generated from synthetic
DVFs for a patient who experienced parotid shrinkage. A linear response model was
assumed (Chapter 2, Materials and Methods), and r = s in equation 2.1, ensuring that
DVFs incorporated approximately 5 times the level of random motion seen in clinical
CBCTs
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Figure 3.5 shows results for RPCA models generated from synthetic DVFs for a
patient who experienced parotid shrinkage. Left and right columns show the projections
of synthetic DVFs onto the two leading EDVFs. A linear response model was assumed
and * was equal to 5, ensuring that the magnitude of fraction-to-fraction random motion
was exaggerated to approximately 5 times the level seen in clinical CBCTs, making it
more difficult for PCA to extract systematic change from the random background.
As in Figure 3.4, plotted points on Figure 3.5 are the means of 5 simulated courses,
and error bars represent ± one standard deviation. Orange points show the EDVF weights
for the first F fractions, synthetic DVFs for which were included in the RPCA model (first
5, half and all-but-last). Blue points show weights for fractions F+1,..., N, synthetic DVFs
for which were excluded from the RPCA model. The orange line is the regression line for
orange points. The blue line is the regression line for all points, orange and blue. Orange
regression lines match the intercept M and slope N in equation 2.4. No blue linear
regression line is shown for the RPCA model generated from all-but-last fraction.
Figure 3.6 shows results for the RPCA models generated from clinical DVFs for a
patient who experienced weight loss in the left neck. In this case, plotted points are
projections of the clinical DVFs onto the first three EDVFs. Higher EDVFs (4+) were
omitted since they accounted for <10% of the total variation. Since clinical data is being
used, there is only one treatment course, and no error bars are plotted. Orange and blue
points and lines are as in Figure 3.5.
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Figure 3.6 RPCA: 1st, 2nd and 3rd EDVF weights for RPCA models generated from clinical
DVFs for a patient who experienced weight loss in the left neck

Figure 3.7 shows additional results — predicted DVFs and eigenimages —

for

the same patient and clinical DVF data as in Figure 3.6. Columns 1 and 2 give results for
SPCA models, columns 3 and 4 for RPCA models. DVFs (green arrows, columns 2 and
4) were generated using equation (5) with K = 3 EDVFs, and the same orange regression
lines as shown in Figure 3.7.
In Figure 3.7, DVF arrow directions represent pull-back displacement fields from
the planning anatomy (pCT) to the final treatment fraction. DVFs are superimposed on
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the pCT image set to facilitate visual evaluation. Figure 3.7 shows DVFs for the same
axial slice through the patient anatomy.

Standard PCA

Figure 3.7 RPCA: Predicted DVFs and corresponding eigenimages (heat map
representation of DVF vector magnitudes) for the same patient as in Figure 3.7. DVF
arrow directions represent pull-back displacement fields from the planning anatomy
(pCT) to the final treatment fraction. The magnitude of displacements is at the same scale
as the background image.
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The eigenimages in columns 1 and 3 of Figure 3.7 are heat-map representations
of the DVFs’ vector magnitude. Colors range from white (large magnitude displacements)
to red (intermediate magnitude displacements) to black (small or zero displacements).
The eigenimages are for the same axial slice as the DVFs.
Figure 3.8 shows the results similar to that shown on Figure 3.7, but for the patient
with parotid shrinkage and weight loss as a major anatomical change during radiotherapy.

Figure 3.8 RPCA: Predicted DVFs and corresponding eigenimages (heat map
representation of DVF vector magnitudes) for the patient with parotid shrinkage and
weight loss as a major anatomical change during radiation therapy.
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Discussion

Qualitative Evaluation
Table 3.1 shows that R2 coefficients for the simulated linear cases for the first
EDVF have values close to 1, while EDVFs 2-5 produce much lower R2 values. This result
shows that the leading first EDVF can capture the simulated linear major mode of
anatomical change, while succeeding EDVFs capture residual errors and noise.
Figure 3.1 shows that RPCA modeling is capable of extracting the major mode of
anatomical change during head and neck radiation therapy. The leading EDVF
coefficients show a smooth progression during treatment, and the more CBCTs that are
included in the PCA model, the better the model becomes. This is indicated by a
progressive tightening of the standard deviations of EDVF weights as one moves from
model A (5 fractions), to model B (18 fractions), to model C (34 fractions).
In Figure 3.1 the modeled anatomical change, left neck lymph node shrinkage, is
large — it affects a relatively large volume of the patient’s anatomy. RPCA searches for
EDVFs that can explain variability across CBCT images. The modeled anatomical change
is large, and, similar to SPCA, the RPCA technique is easily able to ‘extract’ the major
deformation mode(s) from noisy data.
In Figure 3.2 (patient A, worst case for SPCA model), the modeled anatomical
change, bilateral parotid shrinkage, is relatively small — it affects a localized volume
around the parotids. In this case, as with the case on Figure 3.1, RPCA also successfully
isolates systematic anatomical change from other random variations. This is the opposite
of the SPCA modeling results, which had more difficulty in isolating the anatomical
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change from other random variations that are present in the CBCT images. The RPCA
model is successful for patient D. The RPCA models for F=5 fraction show a fairly weak
linear progression of the leading EDVF coefficient, and the standard deviation of the
coefficients is large, indicating that the RPCA technique is having a difficult time ‘locking
onto’ the major deformation mode. But for the case F=18 and 35 the RPCA model become
good enough to predict the anatomy, with a higher level of confidence.
One of the conclusions of this study is that RPCA could successfully extract
smaller systematic anatomical changes from daily CBCT images.

Quantitative Evaluation
Figure 3.3 shows that larger HU errors occur for the RPCA models generated from
clinical CBCTs (lines (a) and (b)), than those generated from synthetic images and DVFs
(lines (c) and (d)). Comparing to SPCA, RPCA is more successful in extracting useful
models from synthetic cases and clinical CBCT images.
This conclusion is reinforced by the gamma results in Table 3.2. Those results
show that the number of voxels in epCT that disagree with pCT by more than 3% or 3
mm is fairly modest for the RPCA models generated from synthetic DVFs, but much larger
in models generated from clinical CBCTs. And in all cases RPCA models have a smaller
number of voxels which fail the 3% and 3mm gamma criteria than the SPCA models.
As for the SPCA models, quantitative results shown in Figure 3.3 and Table 3.2
may be used as an indirect way of testing the accuracy of DVFs, or the accuracy of the
reconstructed epCT versus the pCT image. Results of the quantitative analysis give an
idea of how the number of fractions used to build a model and random changes presented
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in simulated and clinical data affect the quality of the last-fraction DVF and overall
accuracy of the epCT with respect to the pCT image.

PCA Performance
Figure 3.4 illustrates SPCA and RPCA performance under favorable conditions.
Figure 3.4 results are for a synthetic DVF set, where by design only one type of systematic
change is present in the patient data, and the magnitude of random changes is
comparable to clinical CBCTs. As a consequence, the error bars in Figure 3.4 are
relatively small, indicating consistent results across multiple simulated treatment courses.
Under these conditions, the bottom panel in Figure 3.4 shows that PCA can successfully
extract systematic motion using the leading EDVF. In the bottom panel, the curves for
early, linear and late response models mirror the profiles in Figure 2.3 (Chapter 2), as
one might hope. Figure 3.4 confirms that under favorable conditions — i.e., given
sufficient patient data to enable extraction of mean trends in the presence of random
background — PCA modeling can accurately extract the time-profile of anatomical
change.
For all response models, SPCA and RPCA perform well when able to build a model
from 34 fractions (Figure 3.4 bottom panel). When it is limited to half of the fractions
(middle panel), or the first 5 fractions (top panel), PCA continues to perform well for the
early and linear response models — the red and blue curves in the top 2 panels mirror
those in the bottom panel. However, it fails for the late response model in that the profile
of the late response weights in Figure 3.4, top and middle panels, does not mirror the late
response model of anatomical changes as shown in Figure 2.3. This illustrates an
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intuitively obvious fact. PCA can only be successful if it is given sufficient motion data
from which to build a model. In the late response model, there is simply not enough
information present in early fractions for PCA to build a valid model.
The ability of SPCA and RPCA to generate patient-specific models from initial
treatment fractions for late-responding patients will depend on factors such as the size of
anatomical change relative to random motion, and will likely need to be evaluated on a
treatment site-by-site basis. A possible alternative is to develop population-based PCA
models of anatomical change, and use these as a starting point for all patients. Each
patient’s motion model could then be refined as patient-specific data is acquired over the
course of treatment. This work considers only patient-specific SPCA and RPCA models,
generated from a single patient’s data. Population based models represent a direction for
future research, and are not considered here. However, one might hope that populationbased models, based on large volumes of clinical data, could approach the PCA results
shown in the bottom panel of Figure 3.4.
Figure 3.5 illustrates (only) RPCA performance under challenging conditions.
Figure 3.5 results are for a synthetic DVF set, where by design only one type of systematic
change is present in the patient data, but where the magnitude of random changes is
exaggerated with respect to clinical CBCTs. As a consequence, the error bars Figure 3.5
are large, indicating a high degree of variability in DVFs across simulated treatment
courses. Under these conditions, the bottom two rows of Figure 3.5 show that RPCA is
still able to successfully extract systematic change when it has access to 18 of 35, or 34
of 35, fractions. Note that the regression lines in row 2 agree with those in row 3,
suggesting that RPCA is consistently identifying the same mode of motion in each EDVF.

48
What is new in this scenario is that RPCA now captures motion in more than one leading
EDVF. Figure 3.5 column 2 shows that the 2nd EDVF weight has non-zero slope,
indicating that it plays a role in modeling motion. For realistic motion scenarios, it is
expected that PCA will require more than one EDVF in order to faithfully model anatomical
motion.
The top row of Figure 3.5 shows that RPCA breaks down when it only has 5
fractions of data. In this scenario, the orange regression lines based on the first 5 fractions
do not match the blue regression lines based on 34 fractions. The blue lines agree with
lower plots, and so can be assumed to represent the ‘true’ EDVF weights. Predicted DVFs
based on the orange regression lines would be wildly inaccurate for later fractions, and
so produce erroneous predictions of anatomical change, cumulative radiation dose, etc.
This reinforces the conclusion that patient-specific PCA models may have limited utility
when based on a small number of initial fractions. As noted above, it may be desirable to
investigate population-based models to address this limitation.
Figure 3.5 shows results only for a linear response model. The size of error bars
in Figure 3.5 will make it difficult to reliably predict non-linear trends. One could fit different
non-linear curves to patient-specific EDVF coefficients, but the confidence intervals
around the fits may be large. If, however, one were to generate population PCA models
based on large volumes of H&N patient data, one could reasonably hope that average
trends could be extracted. Use of regularized PCA to generate population models remains
a subject for future research.
Figure 3.6 illustrates PCA performance for a clinical case, where the motion that is
present in the H&N CBCT image set is not known a priori. Figure 3.6 results are
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qualitatively similar to those in Figure 3.5. They exhibit similar levels of noise (scatter of
plotted points around the trend lines) as seen in Figure 3.5. As in Figure 3.5, the orange
and blue trend lines in the lower two rows of Figure 3.6 are in good agreement, suggesting
that RPCA is consistently identifying the same mode of motion in each EDVF. The orange
trend lines in row 2 are in reasonable agreement with the blue lines in rows 2 and 3,
showing that an RPCA model based on 18 of 35 fractions can accurately predict EDVF
weight trends for remaining fractions. Note that the trend line associated with each EDVF
can reasonably be interpreted as systematic anatomical change, while the scatter of
points around the trend line represents the superimposed effect of random fraction-tofraction motion. The consistent trend lines in rows 2 and 3 show that RPCA is consistently
identifying the systematic component of anatomical change.
The top row of Figure 3.6 shows that PCA performs poorly when the model is
based on only the first 5 fractions. The orange trend lines do not agree with the blue trend
lines for EDVFs 1 and 2. This conclusion is consistent with the results for simulated DVFs
in Figures 3.4 and 3.5: patient-specific PCA models may have limited utility when based
on a small number of initial fractions.
In practice, weights on Figure 3.6, acquired from the projection of the clinical DVFs
onto the calculated EDVFs, are used to build a patient-specific RPCA model using
equation 2.4. For the RPCA models generated from the first F fractions (e.g., first 5
fractions, half of the fractions, or all-but-last fraction), subsequent weights of the F+1,…,
N fractions are calculated using a linear fit, and these weights are then used in equation
2.4 to model future fractions DVFs and corresponding anatomy.

50
Figures 3.7 and 3.8 provide a visual comparison of the SPCA and RPCA models
which were used to calculate the last fraction DVFs from the first 5, half, and all-but-last
fraction, and visual confirmation that RPCA is better than SPCA at identifying the
systematic component of H&N anatomical change. For reasons discussed below, SPCA
tends to produce noisy EDVFs, which are difficult to relate to clinically observable
changes. In Figures 3.7 and 3.8, SPCA EDVFs are non-zero across the whole patient
anatomy, even though dominant change is clearly confined to the left neck. In contrast,
at least when RPCA models are based on 18+ fractions, RPCA is successful at isolating
the dominant mode of change to the left neck area. RPCA’s ability to identify and
reproduce clinically observed change creates the potential to use RPCA to anticipate and
trigger adaptive re-planning decisions, and for quantitative treatment response
assessment.

Prior Applications of PCA
The idea of using PCA in radiotherapy is not novel. For example, the PCA
techniques were used to model patient-specific inter-fractional organ deformations in
prostate/rectum/bladder45. The results of that work showed that geometric variability is
governed by only the first few patient-specific eigenmodes, and using first 4 eigenmodes
to model organ deformations reduces residual errors to ≤2 mm. The results were later
used to assess the dosimetric detrimental effects that inter-fractional organ deformations
can have on a planned dose distribution47. Coverage-based treatment planning
techniques for prostate cases were also proposed based on the PCA organ deformation
model62. Furthermore, a population-based PCA model was developed and applied to
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prostate cases40, showing that using the first 7 eigenmodes for patients in a database,
and first 15 eigenmodes for patients not in a database, reduces residual errors to ≤1 mm.
The main difference between this research and those described above is that this
work is focused on separating systematic changes in patients’ anatomy from random
changes. While this may not be necessary for the prostate/bladder/rectum cases, since
these areas don’t experience major systematic change during the radiotherapy, this
separation is important for H&N cases, since the anatomy could change significantly
during the treatment course.
The PCA model in H&N patients was also described and performed to create an
organ sample generator (OSG) for expected treatment dose construction63. The OSG
generated random samples of organs of interest during the treatment course to evaluate
dosimetric effects of the organ variations/deformations. The accuracy of the OSG
improved with the number of treatment fractions used for the PCA model, showing
discrepancy of the dose estimation within 1% for most organs after the first 3 weeks of
treatment. The OSG is a useful tool for dose accumulation estimation during the
treatment, but since it’s not trying to separate systematic changes in anatomy from
random changes, it could not be used in the prediction of the end-of-treatment anatomy.

Potential for Regularized PCA
ART promises to improve the quality of treatment received by radiation therapy
patients. However, adoption of ART has been held back by some practical considerations.
Repeatedly re-planning patient treatments can be costly, in terms of physician and
dosimetrist time and physics resources to check and QA treatment plans. There is
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consequently a need for measurement-based models of anatomical change and
treatment response that would allow physicians to make educated decisions about when
to re-plan, which patients will benefit, etc.
RPCA has the potential to solve some of these challenges. RPCA is designed to
extract major modes of deformation from noisy imaging data, in principle allowing one to
discriminate real changes in the anatomy from background noise. If successful, RPCA
could be used to predict the future anatomy, and make re-planning decisions based on
dosimetric impact to the tumor and normal tissues.
SPCA is a well-known tool to find the major modes of variations in real-world
datasets. However, it was developed for datasets where the dimension of the problem is
less than the number of available data samples. In the present problem, the dimension of
the problem is 3M (i.e., 3 times the number of DVF voxels), which is on the order of 104105 for H&N voxel grids, and therefore much larger than the number of available CBCTs.
In this scenario SPCA models are extremely under-determined. As a result, SPCA has
a tendency to produce EDVFs than are noisy, and difficult to relate to clinically observable
anatomical changes.
RPCA addresses the problem of under-determination by supplementing SPCA
with additional constraints on eigenvectors. In the present work, RPCA adds smoothness
and sparseness constraints to SPCA. This has the effect of forcing EDVFs to be smooth
(i.e., physically realistic) and sparse (i.e., confined to localized regions of anatomy where
change is detected). Together, these constraints have a tendency to concentrate detected
anatomical change into a smaller number of leading EDVFs, which in turn makes it easier
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to relate the EDVFs to clinically observable response. The application of regularized PCA
to adaptive radiation therapy is a novel contribution of this work.
This work can be considered to fall within radiomics, which studies how to extract
quantitative information from the medical images in order to characterize treatment
response. In the present case, RPCA is being used to reduce high-dimensional imaging
data to a small number of anatomical motion modes. Detecting tumor deformation during
treatment will permit assessment of treatment response. Similarly, detecting the response
of normal tissues, such as parotid glands, may permit quantitative evaluation of
radiotherapy-related complications.

Study Limitations
Acquiring accurate DVFs between patient images is a key step in this study
because the results of PCA modeling are dependent on the quality of input DVFs.
Therefore, the choice of DIR algorithm and its registration parameters is one of the most
important factors for accurate modeling. In this study Pinnacle’s diffeomorphic demons
algorithm58 was used for deformable registrations. Although we visually verified the
registration results, use of a different algorithm may produce slightly different results from
those presented in this study. In this work other DIR algorithms were not used apart from
those implemented in Pinnacle®, since all the codes for DVFs manipulations were
implemented considering Pinnacle’s® DVF internal structure and performed using
Pinnacle® plugin functionality. One of our intended future works is to use different
commercial and open-source DIR algorithms to understand the effects on the resultant
PCA models.
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Quantification of DIR/DVF accuracy is a major challenge for adaptive radiation
therapy, on which much research is being expended. It is outside the scope of this work
to attempt to quantify the accuracy of DIR algorithms. Instead, we expect that reliable DIR
algorithms will emerge from ongoing research and clinical use. Although DVF accuracy
will have an impact on the accuracy of PCA models, we note that regularized PCA may
be part of the answer to this issue. RPCA has the potential to extract smooth and
physically meaningful EDVFs from noisy CBCT data, including the noise introduced by
DVF uncertainties. One can reasonably hope that RPCA models will be insensitive to
small scale uncertainties present in DVFs, and instead extract larger scale anatomical
changes corresponding to observable clinical change.
One other important study limitation is the CF used to acquire DVFs. In this study,
CF of 7 was used, which reduces the precision of acquired DVFs compared to noncompressed DVFs. This, in turn, reduces the precision of the motion model and could
underestimate the effects of anatomical motion presented in the patient. This effect can
be seen in Figures 3.1 and 3.2 – on the left neck lymph node shrinkage (Figure 3.1) and
parotid shrinkage (Figure 3.2). RPCA does not precisely capture these anatomical
changes due to the large CF used, and epCT is not completely matched to the pCT image,
even though it still shows better performance than SPCA, giving an advantage of better
smoothness and sparseness due to the regularized approach.
The regularized approach in PCA requires a calculation of penalty matrix of very
large size, ~ (3M) 2, which puts very high requirements on computational resources. In
this work, CF of 7 was used, and random-access memory (RAM) of ~ 100-120 GB
(depending on the patient) was required, and calculation time was ~ 7 days on the Wayne
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State University High Performance Computing Grid. The calculation time potentially could
be improved by using a parallel computing – dividing the calculation of the penalty matrix
for RPCA models between multiple processes.

Conclusion
For H&N patients treated with external beam radiation therapy, a PCA model (both
standard and regularized) is a potential tool to identify patient anatomy changes early in
the treatment course, and use these to make educated adaptive re-planning decisions.
This study used synthetic (but realistic) DVFs, as well as clinical CBCTs, to evaluate the
ability of the PCA method to extract useful models of anatomical change. In particular, a
primary goal of this work was to evaluate the ability of PCA to separate systematic from
random changes present in CBCT images.
The study shows that both SPCA and RPCA can capture the major mode of
systematic anatomical deformation in the leading EDVF. However, the SPCA approach
is most successful at identifying large changes (e.g., significant lymph node shrinkage),
and less successful at identifying small changes (e.g., smaller changes in parotid glands).
SPCA is challenged by the variety of deformations and noise in clinical CBCT images,
and therefore fails to extract major modes of systematic change that are known to be
present. Conversely, the RPCA approach is able to identify smaller systematic changes
in the presence of the random fraction-to-fraction changes. The current drawback of the
RPCA approach is the time of the calculation and memory requirements.
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CHAPTER 4 “DOSIMETRIC ASSESSMENT OF EFFECTS OF SYSTEMATIC AND
RANDOM FRACTION-TO-FRACTION ANATOMICAL CHANGES IN HEAD AND
NECK PATIENTS”

Introduction
Decisions about whether to perform ART for a specific H&N patient could be made
by the physician by either comparing the patient’s daily anatomical images (like CBCT)
with the pCT image and deciding if anatomical changes are large enough to significantly
alter the planned dose distribution, or by evaluating the mask used for patient
immobilization and positioning, or using other subjective indicators, such as the
physician’s experience in such cases. Currently, there are no clear quantitative indicators
regarding whether or not perform ART for a specific patient64.
Using advanced treatment techniques like IGRT, one of the potential quantitative
indicators for ART in H&N patients could be the measuring of the actual dose delivered
to date to targets and OARs, which could be done by calculating “dose of the day” onto
re-sampled CT images using DIR and then accumulating it back onto the pCT65. Such
“dose of the day” calculations, which would give accumulated dose up to but not beyond
the current fraction, can be used in the clinic for tracking the dose delivered to the patient
in each fraction and comparing it with the planned dose distributions. The drawback of
this method is that it is retrospective: one can react to OAR overdoses or target
underdoses once they have happened, but there is no good basis for anticipating them
and correcting them in advance, while one still has maximum flexibility to re-plan and
correct the dose distribution.
In this work one of the potential solutions to this problem is presented. Using
developed motion models based on RPCA approach (Chapter 3), not only “dose of the
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day” is calculated and accumulated, but also dose of the future fractions is calculated on
re-sampled “future CT” images. The predicted cumulative dose is then compared to the
planned dose, enabling re-planning decisions to be made earlier in the treatment course.
Additionally, at the end of the course, the predicted cumulative dose can be compared
with the true cumulative dose, to evaluate the accuracy of the RPCA-based dose
predictions.
There are two main hypotheses in this study:
H1: RPCA models can quantify deviations between planned and delivered
cumulative dose caused by systematic anatomical changes.
H2: RPCA models can quantify deviations between planned and delivered
cumulative dose caused by both systematic and random anatomical changes.
This study provides a testing framework to evaluate the accuracy of RPCA-based
anatomical models at predicting cumulative dose. Within this framework it is instructive to
separately calculate the dosimetric effects of systematic versus random changes. In this
way one can assess the relative contributions of systematic versus random changes. One
can then make reliable re-planning decisions based on detected systematic changes, and
determine PTV margins to absorb residual random changes.

Materials and Methods
Two H&N patients from the dataset described in Chapter 2, who experienced large
systematic changes during the course of radiation therapy, were chosen in order to
conduct a dosimetric study. The first of the selected patients experienced parotid
shrinkage, and was treated with 70Gy in 33 fractions. The second selected patient
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experienced parotid shrinkage and weight loss during the course of radiation therapy, and
was also treated with 70Gy in 33 fractions. The following work was performed using
synthetic DVFs containing known localized anatomical changes, derived from the warped
CT (wCT), as described in the “Synthetic Deformation Vector Fields” section of Chapter
2. The corresponding eigenimages and last-fraction DVFs for the second patient are
shown in Figure 3.8.
For the purpose of getting the pCT image, the patients were set up head-first
supine on a CIVCO H&N board (CIVCO Medical Solutions, Coralville, IA) using a 9-point
thermoplastic mask with individually modeled pillow for immobilization. The treatment
plan was prepared and optimized within the Eclipse TPS (Varian Medical Systems, Palo
Alto, CA) using the Analytical Anisotropic Algorithm (AAA). For daily CBCT images, the
following parameters were used: 120 kVp, 20 mA, 150 cm source-to-detector distance.
For the hypothesis H1, the cumulative dose was calculated for the systematic
change only using the RPCA models described in Chapter 3:
(i) Synthetic DVFs, based on the linear response model, and containing the
systematic component only (random excluded) were taken (equation 2.1, with DR=0) for
each of 33 fractions. These DVFs were inverted using the ITK66 software library: the
synthetic DVFs map coordinates from a space of pCT into a space of daily anatomy (i.e.
CBCT), and the inverse synthetic DVFs map coordinates from the space of daily anatomy
into the space of pCT. These inverse DVFs are then used to get day-of–treatment
anatomy from the pCT for each of 33 fractions, which in turn are used to get cumulative
dose (dose A). This data simulates anatomies, bi-directional DVFs, and daily CTs for a
full treatment course.
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(ii) Using the RPCA model (Chapter 3, Materials and Methods) and synthetic DVFs
from step (i), predicted DVFs were calculated using first 5, half and all but last treatment
fractions. Inverse DVFs and predicted CT images for each of 33 fractions were acquired
and used to predict cumulative dose (dose B) at the final fraction.
(iii) The above procedure generates three dose distributions:
-

Planned dose: This is the original planned dose distribution generated on

the planning CT
-

Dose A: For a simulated treatment course, this is the “true” cumulative dose

at the end of the course, assuming zero random changes.
-

Dose B: For a simulated treatment course, this is the dose predicted by an

RPCA model, where the model could be derived from the first 5, half, or all but last
simulated fractions, assuming zero random changes.
For relevant structures, Dose Volume Histograms (DVHs) for 3 scenarios were
compared: planned dose, dose A, and dose B. If H1 is correct, the expectation is to see
dose A similar to dose B. In this study “similarity” was checked by comparing the
maximum and the mean dose deviations between doses A and B which were expected
to be close enough to be clinically equivalent. We also expect that doses A and B can
differ significantly from the planned dose, depending on structure, due to the presence of
significant anatomical changes over the treatment course.
For hypothesis H2, the cumulative dose was calculated for both systematic and
random changes using the RPCA models:
(iv) Synthetic DVFs, based on the linear response model, and containing both
systematic component and 10 different simulations of random components were taken
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(equation 2.1) for each of 33 fractions. Using the same procedure as in step (i), these
DVFs were inverted and then used to get cumulative dose in the presence of systematic
and random components (dose C).
(v) Using RPCA model and synthetic DVFs with simulated random components
from step (iv), predicted DVFs were calculated using first 5, half and all but last treatment
fractions, inverse DVFs and predicted CT images for each of 33 fractions were acquired
and used to get cumulative dose (dose D).
(vi) The above procedure generates three dose distributions:
-

Planned dose: This is the original planned dose distribution generated on

the planning CT
-

Dose C: For a simulated treatment course, this is the “true” cumulative dose

at the end of the course, assuming non-zero random changes.
-

Dose D: For a simulated treatment course, this is the dose predicted by an

RPCA model, where the model could be derived from the first 5, half, or all but last
simulated fractions, assuming non-zero random changes.
In the same manner as above, for relevant structures, DVHs for 3 scenarios were
compared: planned dose, dose C, and dose D. If H2 is correct, the expectation is to see
dose C similar to dose D, and both of these different from the planned dose.
A CF of 7 was used for this study for the reasons discussed in Chapter 3 –
generation of RPCA models using our current method is numerically and memory
intensive, so it was necessary to adopt a CF of 7 in order to keep computing resources
and execution times within acceptable limits.
However, aggregation of DVF voxels has the effect of smoothing DVFs, reducing
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their spatial resolution, at least in the XY-plane. As shown in Chapters 2 and 3 (Figures
2.5, 2.6, 3.1, 3.2), using large CF for the acquisition of the DVFs could underestimate the
anatomical motion in the patient even if it was captured correctly in the CBCTs.
To assess this effect, the predicted dose from RPCA models (where anatomical
motion could be underestimated due to DVF compression) was compared to the “real”
accumulated dose and to the planned dose. “Real” dose accumulation (dose R) was
performed in VelocityAI (version 3.2.0, Varian Medical Systems) using the method
described in Kumarasiri et al67. Acquiring dose R does not require DVFs compression,
and therefore it accounts for all anatomical motion, subject to the DIR precision and
uncertainty.
Dose R is then compared to planned dose, and doses A, B, C and D. If compressed
DVFs in fact underestimate the anatomical changes in the patient, dose R is expected to
be different from the planned dose, and the DVHs associated with doses A, B, C and D
are expected to be in between the DVH of the planned dose and DVH of the dose R.
The percent differences between the planned dose and simulated (dose A, C),
modeled (dose B, D), or accumulated dose (dose R) was calculated using the following
equation:
∆

=$

uv w/wxyz{/|}}~w u•{|€€zy
'
u•{|€€zy

× 100

(4.1)

Results
Figures 4.1 and 4.2 show the DVHs for the left parotids of patients 1 and 2. On
these figures, planned DVH (blue) is compared to the calculated DVHs of patients 1 and
2 with the systematic only (Figure 4.1, dose A, green) and systematic and random
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components (Figure 4.2, dose C, green) superimposed on this patient during the course
of radiation therapy. The anatomy of these patients was also predicted using the RPCA
models for the first 5, half and all but last treatment fractions and corresponding predicted
DVHs are shown on Figures 4.1 (dose B) and 4.2 (dose D) as purple, dark blue and brown
dashed lines respectively.

Figure 4.1 DVHs for the left parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only
component superimposed on the patient’s anatomy during the course of radiation therapy,
and also compared to the modeled DVHs (doses B) for the predicted anatomies from the
RPCA models built using the first 5 (purple), half (dark blue) and all but last treatment
fractions (brown).
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Figure 4.2 DVHs for the left parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line.
Figure 4.3 and 4.4 show the DVHs for the right parotids of the patients 1 and 2.
The information is similar to that shown in Figures 4.1 and 4.2.

64

Figure 4.3 DVHs for the right parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only component
superimposed on the patient’s anatomy during the course of radiation therapy, and also
compared to the modeled DVHs (doses B) for the predicted anatomies from the RPCA
models built using the first 5 (purple), half (dark blue) and all but last treatment fractions
(brown).

Figure 4.4 DVHs for the right parotids of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line.
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Figures 4.5 and 4.6 show the DVHs for the spinal cords of the patients 1 and 2.
The information is similar to that shown in Figures 4.1, 4.2, 4.3 and 4.4.

Figure 4.5 DVHs for the spinal cords of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVH (dose A) of the patient with the systematic only component
superimposed on the patient’s anatomy during the course of radiation therapy, and also
compared to the modeled DVHs (doses B) for the predicted anatomies from the RPCA
models built using the first 5 (purple), half (dark blue) and all but last treatment fractions
(brown).
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Figure 4.6 DVHs for the spinal cords of the patients 1 and 2. Planned DVH (blue) is
compared to the simulated DVHs (dose C) of the patient with the systematic and random
components superimposed on the patient’s anatomy during the course of radiation
therapy, and also compared to the modeled DVHs (doses D) for the predicted anatomies
from the RPCA models built using the first 5 (purple), half (dark blue) and all but last
treatment fractions (brown). Grey dotted lines represent the standard deviation of the
green line.
Figure 4.7 (A) shows the pCT image (red) overlaid on the resampled CBCT image
of the last treatment fraction for the patient 2 who experienced parotid shrinkage and
weight loss during the course of radiation therapy. The CBCT is resampled using the
diffeomorphic demons DVF compressed with a CF of 7. Figure 4.7 (B) shows the pCT
image (red) overlaid on the epCT (green) for this patient; the epCT image is acquired
using equation 2.4 from Chapter 2. Red arrows show the underestimation of the parotids
movement due to the large CF used for the DVFs. Figure 4.7 (C) shows the pCT image
(red) overlaid on the last fraction CBCT image.
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Figure 4.7 Patient 2: (A) pCT (red) overlaid on the resampled CBCT of the last treatment
fraction. CBCT is resampled using the diffeomorphic demons DVF compressed with the
factor 7; (B) pCT (red) overlaid on the epCT (green). Red arrows show the
underestimation of the parotids movement due to the large CF used for the DVFs; (C) pCT
(red) overlaid on the last fraction CBCT (green).
Figures 4.8, 4.9 and 4.10 show the results of the movement underestimation of the
patients anatomy by the DVFs by comparing the planned (blue) and modeled (green and
brown) DVHs presented above with the “real” accumulated DVH (red) for the left and right
parotids, and spinal cord.

Figure 4.8 Patients 1 and 2: Comparison of the planned DVHs (blue) for the left parotid
glands vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH.
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Figure 4.9 Patients 1 and 2: Comparison of the planned DVHs (blue) for the right parotid
glands vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH.

Figure 4.10 Patients 1 and 2: Comparison of the planned DVHs (blue) for the spinal cords
vs. the simulated DVHs (green, brown) vs. “real” cumulative DVH.
Table 4.1 summarizes the cumulative dosimetric parameters of the OARs for
both patients 1 and 2. Mean and maximum doses for the parotid glands, and maximum
dose for the spinal cord are compared between planned, simulated (using both
systematic and random components), modeled (using both systematic and random
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components) and cumulative cases. The relative difference from the planned dose
(equation 4.1) is presented in parentheses.

Left
parotid

Planned
Simulated, dose C
5fx
Modeled,
dose D

Half
All

Cumulative
Right
Parotid

Planned
Simulated, dose C
5fx
Modeled,
dose D

Half
All

Cumulative

Spinal
Cord

Planned
Simulated, dose C
5fx
Half
Modeled,
All
dose
D
Cumulative

Patient 1
Dmean
Dmax
23.5
51.0
25.1
54.1
(6.8%)
(6.1%)
23.7
52.5
(0.9%)
(2.9%)
25.1
53.9
(6.8%)
(5.7%)
25.7
54.3
(9.4%)
(6.5%)
27.0
55.9
(14.9%)
(9.6%)
23.0
51.8
24.5
54.3
(6.5%)
(4.8%)
23.5
51.0
(2.2%)
(-1.5%)
24.9
54.8
(8.3%)
(5.8%)
24.4
54.3
(6.1%)
(4.8%)
25.7
55.1
(11.7%)
(6.4%)
Dmax
42.1
43.9 (4.3%)
42.9 (1.9%)
43.3 (2.9%)
43.5 (3.3%)
45.2 (7.4%)

Patient 2
Dmean
44.6
49.8
(11.7%)
46.6
(4.5%)
49.3
(10.5%)
50.5
(13.2%)
52.5
(17.7%)
41.7
47.9
(14.9%)
44.5
(6.7%)
47.1
(12.9%)
48.6
(16.5%)
50.1
(20.1%)

Dmax
74.4
75.9
(2.0%)
74.9
(0.7%)
75.6
(1.6%)
75.7
(1.7%)
76.6
(3.0%)
65.2
67.9
(4.1%)
66.3
(1.7%)
67.8
(4.0%)
68.7
(5.4%)
69.8
(7.1%)

Dmax
45.2
45.2 (0%)
44.9 (-0.7%)
45.3 (0.2%)
45.3 (0.2%)
45.4 (0.4%)

Table 4.1 Planned, simulated, modeled and accumulated dosimetric parameters for the
patients (in Gy). The relative percentage difference from the planned dose presented in
parentheses.
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Discussion
Figures 4.1, 4.3 and 4.5 show the DVHs for the simulated and modeled left parotid,
right parotid and spinal cord respectively when only systematic changes are introduced
in patients 1 and 2 with parotid shrinkage, and parotid shrinkage and weight loss as a
major mode of anatomical change during radiation therapy, respectively. These are
compared to the planned DVH. It can be seen qualitatively that the planned dose to the
parotids is different from the simulated (Figures 4.1, 4.3, dose A) and modeled doses
(Figures 4.1, 4.3, dose B). Due to the shrinkage, the parotids are shifted into the area of
higher dose and accumulate more dose than was planned. However, changes in the
parotids did not affect the movement of the spinal cord of the patient 2 during the radiation
therapy course, and the dose to the spinal cord didn’t change for the simulated course
compared to the planning course. On the other hand, as shown in Table 4.1, patient 1
experienced dose escalation from the planned (42.1Gy) to simulated (45.2Gy) treatment
course. While in this case this unintended 3 Gy increase in the dose to a critical OAR
would likely be acceptable24, this is not always the case. For example, if the modeled
maximum dose to the spinal cord had been 55 Gy, additional dose in such case would
predict a substantial increase in Normal Tissue Complication Probability (NTCP).
For the patients 1 and 2, RPCA anatomy modeling when using DVFs from the first
5 fractions qualitatively showed larger deviation from the simulated treatment course for
the parotids, especially in the areas of higher doses (Figures 4.1, 4.3). RPCA models
when using DVFs from the half and all-but-last fraction show good conformity with the
simulated treatment course. This means that when using enough data for building the
model, RPCA can identify and capture the major mode of anatomical change and it can
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be used to model the anatomy of the future fractions. For the case of the spinal cord the
planned, simulated (dose A), and modeled (doses B) DVHs didn’t show much qualitative
(Figure 4.5) or quantitative (Table 4.1) difference compared to the parotid glands for
patient 2. For patient 1, the DVHs show an increase in dose for both simulated (dose A)
and modeled (doses B) cases. The results in figures 4.1, 4.3, 4.5 and Table 4.1 support
the hypothesis H1, which means that RPCA models can quantify deviations between
planned and delivered cumulative dose caused by systematic anatomical changes given
sufficient patient data to enable extraction of mean trends in the presence of random
background.
Figures 4.2, 4.4 and 4.6 show the DVHs for the simulated (dose C) and modeled
(doses D) left parotid, right parotid and spinal cord respectively when systematic and
random changes are introduced in the patients 1 and 2. These are compared to the
planned DVHs. As demonstrated above, qualitatively the planned dose to the parotids is
different from the simulated (Figures 4.2, 4.4, dose C) and modeled ones (Figures 4.2,
4.4, dose D). Quantitative differences between these doses are presented in Table 4.1.
Similarly to the case with only systematic changes applied, due to the shrinkage, the
parotids are shifted into the area of the higher dose and accumulate more dose than was
planned. Even when random changes are introduced to the patients 1 and 2, this did not
affect the movement of the spinal cord in patient 2 during the radiation therapy course,
and the dose to the spinal cord of the patient 2 didn’t change (Table 4.1) for the simulated
course compared to the planning course. This means that even in the presence of noise,
RPCA is able to differentiate it from the systematic anatomical changes and such random
changes are mostly ignored by the model due to the use of the sparseness parameter i( .
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RPCA anatomy modeling when using DVFs from the first 5 fractions showed larger
deviation from the simulated treatment course for both parotids (Figures 4.2, 4.4, Table
4.1), especially in the areas of higher doses. But RPCA models built using DVFs from the
half and all-but-last fraction show good conformity with the simulated treatment course.
That also means that RPCA can identify and capture the major mode of anatomical
change even in the presence of the random changes and it can be used to model the
anatomy of the future fractions. For the spinal cord of the patient 1 (Figure 4.6), planned,
simulated (dose C) and modeled (doses D) showed the difference of up to 3.3% (Table
4.1) from the planned DVH. For the spinal cord of the patient 2 (Figure 4.6), planned,
simulated (dose C) and modeled (doses D) DVHs didn’t show much difference (<1%,
Table 4.1) from planned DVH compared to the parotid glands. The results in figures 4.2,
4.4 and 4.6 support the hypothesis H2, which means that RPCA models can quantify
deviations between planned and delivered cumulative dose caused by both systematic
and random anatomical changes.
The RPCA models in this work used DVFs acquired using a large CF value (7),
and using such compressed DVFs usually underestimates the anatomical changes
present in the patients. Figure 4.7 (A) shows the pCT image (red) overlaid on the
resampled CBCT image of the last treatment fraction. CBCT is resampled using the
diffeomorphic demons DVF compressed with a factor of 7. Figure 4.7 (B) shows the pCT
image (red) overlaid on the epCT (green) of the patient. Figure 4.7 (C) shows the pCT
image (red) overlaid on the last fraction CBCT image (green). Ideally, it is expected that
pCT and epCT images would be exactly the same, but as can be seen in Figure 4.7 (B),
motion of the parotids is underestimated by the model due to the large CF of the DVFs.
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Such effects are not only seen on the epCT image acquired from the modeled DVFs, but
also on resampled last fraction CBCT image acquired using real clinical DVFs
compressed with the same CF, as seen on Figure 4.7 (A). This means that even though
RPCA could capture the correct major mode of anatomical changes in the patient from
compressed DVFs, it is possible that these changes would be underestimated and the
model will show less movement in the anatomy than in the real case. Another challenge
of using the compressed DVFs is that they can’t capture the movement on a “wiggly”
edge, like those on the parotids in Figure 4.7. So using a large CF will suppress the
smaller and “wigglier” anatomical changes in the DVFs, and therefore RPCA would not
be able to extract such changes form this dataset. In general, the quality of the RPCA
models is dependent on the quality of the input data, the DVFs.
Such underestimation of the anatomical changes could lead to the underestimation
of the dose distribution changes in the patient. This effect is shown for the parotids and
spinal cords of the patients 1 and 2 on Figures 4.8, 4.9 and 4.10. On these figures,
planned DVH (blue) is compared to the simulated DVH, acquired from the anatomy
resampled with the compressed DVFs (green, brown), and in turn compared to the “real”
accumulated DVH (red) for the patient. As can be seen, the “real” DVH is shifted to the
right with respect to the modeled DVHs. This means that underestimation of the parotid
shrinkage in the modeled cases leads to the underestimation of the dose received by
parotids due to their shift into the high dose region.
Based on the visual examination of the performance of the compressed DVFs
(Figure 4.7), and subsequent dosimetric DVHs’ deviations calculated based on these
corresponding DVFs (Table 4.1), future work on RPCA models requires use of DVFs with
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smaller CF in order to capture smaller changes in the anatomy.

Conclusion
This work showed that RPCA has the potential to identify the major mode of
anatomical changes during the radiotherapy course in which allows the prediction of
dose for the course of treatment. There are some challenges presented with the DVFs
compressed using a large CF, so use of smaller CF should be considered for the future
work. There is a hope, that using RPCA modeling could provide a roadmap for how to
use PCA in ART: (i) RPCA models are generated based on initial fractions, (ii) dose
deviations due to underlying systematic change are projected for future fractions to
trigger re-planning decisions, (iii) effects of random changes are superimposed to guide
what margins should be used.
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CHAPTER 5 “CONCLUSIONS AND FUTURE WORK”

Summary of Findings
As discussed in Chapter 1, the modeling of anatomical changes over the course
of head-and-neck treatment is essential to answer practical questions such as: What
anatomical changes are important? How do we measure them? When to trigger replanning? And how best to perform the re-planning? Such models should take into
account not only rigid body transformations but also deformations, and be capable of
extracting useful information about changes in patient anatomy, ideally early in the
radiation treatment course.
PCA was chosen as a core element of this work because of its use in developing
motion models of anatomical changes during the radiation therapy course. PCA has been
used in many previous applications, specifically in the field of radiation therapy47, 49-52.
However, the implementation of PCA models has not been utilized for extracting
systematic changes in patient anatomy during a H&N radiation therapy course.
Two approaches to the PCA were implemented: a standard approach to PCA
(SPCA, Chapter 2) and a more advanced regularized approach (RPCA, Chapter 3).
The results showed that for the H&N patients treated with external beam radiation
therapy included in this cohort, a SPCA model was a potential tool for identifying patient
anatomy changes early in the treatment course, and making educated adaptive replanning decisions. The study showed that under the right conditions, SPCA can capture
the major mode of systematic anatomical deformation in the leading EDVF. However,
SPCA is most successful at identify large changes (e.g., significant lymph node
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shrinkage), and less successful at identifying small changes (e.g., smaller changes in
parotid glands). Additionally, SPCA is challenged by the variety of deformations and noise
in clinical CBCT images, and therefore fails to extract major modes of systematic change
that are known to be present.
In order to successfully model anatomical changes in clinical CBCT images, the
basic SPCA technique has been refined using a regularized approach to the PCA, RPCA
(Chapter 3). Using a regularized approach, we have shown that the RPCA model is a
potential tool for identifying patient anatomy changes early in the treatment course. In
contrast to SPCA, the RPCA approach was able to identify smaller changes compared to
the random fraction-to-fraction changes. The drawback of the RPCA approach is the time
necessary for the calculation, memory requirements and use of large CF for the DVFs.
The dosimetric study (Chapter 4) showed that PCA models have the potential to
identify the major mode of anatomical changes during the radiotherapy course which
allow the prediction of dose for the treatment course. There were some challenges
presented with the DVFs compressed using a large CF, so using smaller CF should be
considered in future work. In summary, the work presented provides direction for the
implementation of RPCA modeling in ART.

Future Work
One of the main directions of the current research going forward is the
accumulation of the H&N patient datasets in order to create population-based models of
anatomical changes. Population based models will be generated from large numbers of
patients, and should therefore capture modes of anatomical change that apply to most
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patients, even if the relative weighting of those modes differs across individuals.
Population-based models should therefore provide a good starting point for predicting
anatomical changes that are expected during the course of treatment, for the majority of
patients. For many patients, it may be necessary to make only minor changes to the
population model, in order to model the patient-specific anatomical change.
For patients who do not fall into the above category, projection of early fractions
onto the population-based EDVFs should allow one to detect significant deviations from
the population-based model. That is, it should allow one to identify the minority of ‘outlier’
patients whose major modes of anatomical change differ significantly from the majority of
patients. This in turn will trigger one to develop a patient-specific model, and carefully
model changes within outlier patients, for unexpected dosimetric consequences.
Population-based models will be useful for triggering customized treatment strategies for
outlier patients.
DVFs which are used as an input for the PCA define an overall quality of the model.
It has been showed in Chapter 4 that using DVFs with large CF could underestimate the
effects of anatomy motion in the patients, and moreover limit the ability to detect the
movement on “wiggly” edges. Therefore PCA also is unable to detect such changes,
which potentially could be important. So, in the future, the use of less compressed or noncompressed DVFs should be considered. The regularized approach requires a calculation
of very large penalty matrices which in turn requires a lot of time, so the compromise
between DVF’s CF and time of calculation should be found. The hope is that with further
advancement in computing technologies, calculations of such large datasets will be faster
and cheaper.
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The quality of the DIR is also closely related to the quality of the PCA models.
DVF accuracies have an impact on the accuracies of PCA models, but one can
reasonably hope that RPCA models will be insensitive to small scale uncertainties present
in DVFs, and instead extract larger scale anatomical changes corresponding to
observable clinical change. Even though checking the quality of the DIR was not an aim
of this work, using different DIR algorithms with different parameters and assessing their
effects on the quality of the PCA models should be considered in future studies.
Another area of the research pertains to improving RPCA, particularly in optimizing
the smoothness (i ) and sparseness (i( ) parameters, while solving the constrained
optimization problem (equation 3.1). In this work these parameters were optimized
empirically with the assumption that sparseness parameter should have a larger weight
than the smoothness parameters due to intrinsic smoothness of the DVFs acquired with
the large CF. However, future work should include further study of these parameters in
order to find which ones are optimal, especially in light of population-based model
developments.
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APPENDIX
STANDARD PRINCIPAL COMPONENT ANALYSIS MATRIX OPERATIONS
Each column in a set of DVFs ‚ = .

,…,

Y0

form a vector

∈ …

_

, where i is

the treatment fraction number, and M is the number of voxel elements in DVF. Each DVF
(column) could be represented as follows:
= $A , , A(, , … , A_, , l , , l(, , … , l_, , m , , m(, , … , m_, '

(A.1)

where x, y, and z are the displacement vector field components in each direction for each
DVF voxel, and ()T is denoted the transpose of the vector, making it 3M x 1 DVF vector.
then could be composed into a matrix ‚$†' ∈ …

Each vector

_×

, where n

corresponds to a number of initial treatment fractions used for PCA analysis, with the
minimum of 2 initial fraction, and a maximum of the whole number of fractions, i.e. 35, or
n=2÷35:
‚$†' = $

,

(, … ,

'

(A.2)

The PCA analysis and predictive model is built using this ‚$†' matrix.
The larger the number of treatment fractions n used as input data for PCA, the
larger the chance that the model could capture systematic changes in the patient.
Therefore, one faces an important trade-off here: the purpose of the model is to reliably
capture systematic changes, which is more likely when the number n of treatment
fractions used to build a model is high, but the other purpose is to capture these changes
early enough, so ART can still be applied to that patient.
Covariance matrix for ‚$†' represented as:
‡ = ‚$†'‚$†'

(A.3)

which generalizes the variance to 3M x 3M dimension. Determining 3M
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eigenvalues and 3M corresponding eigenvectors is a complex, intractable and, after all,
unnecessary task. There are computationally more feasible and much faster methods to
find these. This alternative method is useful when the number of measurements is much
less than number of dimensions, or n<<M.
First, substitute A.3 into the eigenvector equation:
‚$†'‚$†' ˆ$†' = ‰ˆ$†'

(A.4)

ˆ$†' represent eigenvectors for the covariance matrix C, and ‰ are the
corresponding eigenvalues.
Multiplying both sides of A.4 by ‚$†' and defining Š$†' = ‚$†' ˆ$†' gives us:
‚$†' ‚$†'Š$†' = ‰Š$†'

(A.5)

A.5 is a reformed equation which gives us eigenvalues and eigenvectors of smaller
matrix of the size n x n: ‚$†' ‚$†'.
Multiplying both sides of A.5 by ‚$†':
‚$†'‚$†' $‚$†'Š$†'' = ‰$‚$†'Š$†''

(A.6)

Thus from A.5 it follows that eigenvectors for the covariance matrix С defined in
A.3:
ˆ $†' =

‹Œ

‚$†'Š $†'

Where the factor

‹Œ

(A.7)
is used to renormalize the eigenvector ˆ $†', such as

‖ˆ $†'‖ = 1.
These eigenvectors ˆ $†' are defined as EDVFs in this work and they represent
mutually independent vector fields with the maximum number of meaningful EDVFs n-1
(one of the EDVFs corresponds to the zero eigenvalue and is not meaningful).
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Thus, the matrix of meaningful EDVFs has the form ˆ$†' ∈ •Žg×$•

f'

, where each

column represents each EDVFi, and the EDVF1 corresponds to the largest eigenvalue
positioned at the first column of ˆ$†', the EDVF2 corresponds to the second largest
eigenvalue, etc.
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ABSTRACT
PCA-BASED ANATOMICAL MOTION MODELS FOR USING IN ADAPTIVE
RADIATION THERAPY OF HEAD AND NECK CANCER PATIENTS
by
MIKHAIL A. CHETVERTKOV
August 2016
Advisor:

Dr. Indrin J. Chetty
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Medical Physics

Degree:

Doctor of Philosophy

Purpose: To develop standard and regularized principal component analysis
(PCA) models of anatomical changes from daily cone beam CTs (CBCTs) of head and
neck (H&N) patients, assess their potential use in adaptive radiation therapy (ART), and
to extract quantitative information for treatment response assessment.
Methods: Planning CT (pCT) images of H&N patients were artificially deformed to
create “digital phantom” images, which modeled systematic anatomical changes during
Radiation Therapy (RT). Artificial deformations closely mirrored patients’ actual
deformations, and were interpolated to generate 35 synthetic CBCTs, representing
evolving anatomy over 35 fractions. Deformation vector fields (DVFs) were acquired
between pCT and synthetic CBCTs (i.e., digital phantoms), and between pCT and clinical
CBCTs. Patient-specific standard PCA (SPCA) and regularized PCA (RPCA) models
were built from these synthetic and clinical DVF sets. Eigenvectors, or eigenDVFs
(EDVFs), having the largest eigenvalues were hypothesized to capture the major
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anatomical deformations during treatment. Modeled anatomies were used to assess the
dose deviations with respect to the planned dose distribution.
Results: PCA models achieve variable results, depending on the size and location
of anatomical change. Random changes prevent or degrade SPCA’s ability to detect
underlying systematic change. RPCA is able to detect smaller systematic changes
against the background of random fraction-to-fraction changes, and is therefore more
successful than SPCA at capturing systematic changes early in treatment. SPCA models
were less successful at modeling systematic changes in clinical patient images, which
contain a wider range of random motion than synthetic CBCTs, while the regularized
approach was able to extract major modes of motion. For dose assessment it has been
shown that the modeled dose distribution was different from the planned dose for the
parotid glands due to their shrinkage and shift into the higher dose volumes during the
radiotherapy course. Modeled DVHs still underestimated the effect of parotid shrinkage
due to the large compression factor (CF) used to acquire DVFs.
Conclusion: Leading EDVFs from both PCA approaches have the potential to
capture systematic anatomical changes during H&N radiotherapy when systematic
changes are large enough with respect to random fraction-to-fraction changes. In all
cases the RPCA approach appears to be more reliable than SPCA at capturing
systematic changes, enabling dosimetric consequences to be projected to the future
treatment fractions based on trends established early in a treatment course, or,
potentially, based on population models. This work showed that PCA has a potential in
identifying the major mode of anatomical changes during the radiotherapy course and
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subsequent use of this information in future dose predictions is feasible. Use of smaller
CF values for DVFs is preferred, otherwise anatomical motion will be underestimated.
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